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ABSTRACT 
 
Objective 
The primary objective of this study was to explore a new methodological framework - Strategic 
Value Driver Model (SVDM), for examining value drivers for new pharmaceutical inhaled 
insulin in diabetes. 
 
Methods 
A cross-sectional, internet-based survey was used to collect a sample of 483 Type 2 diabetic 
patients via national panel of diabetic patients. The sample had two subgroups - insulin-naïve 
(52.9%, n=255) and insulin-user (47.1%, n=227) patients. The comparative performance of 
insulin syringes/vials, insulin pen and inhaled insulin was captured on four product attributes 
(i.e., safety, convenience, clinical efficacy and cost) after asking the patients to report the 
importance of these attributes. The preference for inhaled insulin was used as dependent variable 
for running multivariable logistic regression with summated-scale score variables for the 
performance of the products as independent variables. 
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Results  
The respondents had an average age of 58 years. After considering product profiles and out-of-
pocket monthly cost of three products, insulin pen and inhaled insulin were equally preferred 
products (by 36.9% and 36.3% of patients, respectively). The preference for inhaled insulin was 
significantly higher among insulin naïve patients (48.2% insulin naïve vs. 22.8% insulin users). 
Performance differentiation between inhaled and pen insulin on clinical efficacy and 
convenience significantly predicted the preference for inhaled insulin; whereas, performance 
differentiation between inhaled and syringe/vial insulin on clinical efficacy, safety and 
convenience significantly predicted the preference for inhaled insulin. A higher percentage of 
insulin naïve patients placed high importance on clinical efficacy, safety and convenience than 
insulin-user patients (76.9% vs. 65.8% for efficacy, 81.6% vs. 68.4% for safety, and 54.5% vs. 
45.2% for convenience, respectively). The two subgroups were found to be different in terms of 
predictors for the preference of inhaled insulin.  
 
Conclusion 
It will be critical for the manufacturer of new inhaled insulin to develop strategies to minimize 
out-of-pocket cost for the patient, along with promoting the clinical efficacy and safety of the 
new product. Furthermore, the results suggest that insulin naïve patients may be a potential 
market for this new inhaled insulin. A major limitation for this study was that almost all of the 
insulin-users had prior experience with Exubera (N=222, 97.4%), therefore, future research is 
required to examine patients with no prior experience of Exubera. 
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CHAPTER I - INTRODUCTION 
         
            New drug products are the center of attention in every pharmaceutical company because 
of high development costs, low probabilities of technical success and uncertain market impact. 
Almost half of the resources that the U.S. pharmaceutical industry devotes to the development of 
new drug products are spent on products that have failed or been discontinued (Blau, Pekny, 
Varma, & Bunch, 2004). In a generation of growing competition from generics and “me-too” 
drugs, along with heightened sensitivity to healthcare spending, pharmaceutical companies have 
been forced to adopt a range of strategies to respond to the changing market dynamics, like 
mergers with other pharmaceutical firms, relying on biotechnology and other research firms to 
provide new drug molecules under licensing, promoting new drug products with the help of new 
technologies like e-detailing, and publicizing attributes of drug products to potential patients, 
swaying them to seek prescriptions from their doctors (Rasmussen, 2002). These companies need 
to invest in better research programs to launch new products successfully, especially products 
that are in a late stage of development. Pharmaceutical companies need to promote and explain 
the incremental value of the new drug product in order to gain competitive advantages in the 
same drug class (Kolassa, 2009).  
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Criticality of product differentiation in promoting a drug product  
            Pharmaceutical companies try to develop new drugs products that are superior to their 
predecessors in some form or another with the hope that they will be quickly accepted.  But the 
fate of every new drug product is not the same, and its success depends on the development of 
marketing strategies for the introduction of new drug products as much as the development of the 
drugs themselves. When a new drug shows promise, a marketing strategy should be devised to 
effectively differentiate the drug product from its competitors, capitalizing on its distinctive 
strengths to deliver better value to its customers. This process becomes more critical when the 
market under consideration is crowded and there are multiple choices. The diabetes market is a 
good example of such a crowded and competitive pharmaceutical market. 
            Although safety and efficacy data from the clinical trials are the most important factors 
influencing the acceptance of a new drug product, when the drug products are not strongly 
differentiated on safety and efficacy, factors like patient preference, and, more importantly, cost, 
influence the decisions of gatekeepers (e.g., physicians), and pharmacy and therapeutic (P & T) 
committees (Eriksen & Keller, 1993). Therefore, in an era of high competition, it becomes 
critical for pharmaceutical manufacturers to identify and target innovation-prone consumers by 
effectively demonstrating the differentiation between available products and the new product.   
 
Patient Preferences 
            Patient needs and perceptions are changing as the demand for better healthcare grows, so 
has the desire for new and better treatments for conditions such as breast cancer, cardiovascular 
disease, hepatitis and diabetes. Patients are becoming more educated and involved in their 
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disease and medication selection. They are also becoming more cost sensitive due to various 
efforts by third-party payers (such as insurance companies, employers, etc.) and agencies like 
AARP (American Association of Retired Persons) to promote the use of generics. In the process 
of learning about a disease and its cure, a patient tends to develop preferences for certain 
pharmaceutical products based on the information he/she gathers from various sources like drug 
advertisements, internet, and health care providers (Hesse et al., 2005).  
            Many decisions need to be individualized, especially when they involve choices between 
possible outcomes that may be valued in a different manner by individuals. For situations like 
these, where a patient has to select from the competing alternatives on the basis of product-
related attributes, patient preference models are useful for understanding patient behavior. 
Furthermore, a better understanding of patients’ assessments of the value of drug product 
attributes could provide pharmaceutical manufacturers with patients’ perceptions about their 
drug products in comparison to already available products in the market.  
            Response to new products has also been studied with the help of diffusion models which 
provides some insights of adoption patterns for new technologies or products and published in 
marketing literature (Phillips, Johnson, & Maddala, 2002). Although they have been used for 
forecasting sales, and to direct pricing and advertising strategies (Phillips et al., 2002), little 
research has been conducted to explore the process of developing preferences for new products 
by individual patients.  
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Value Assessment 
            The concept of “customer value” (CV) is widely used in marketing literature because of 
its important role in predicting purchase behavior and achieving sustainable competitive 
advantage (Zeithaml, 1988; Bolton & Drew, 1997; Cronin, Brady, & Hult, 2000; Dodds, 
Monroe, & Grewal, 1991; Mark & Swait, 2003). Evans (2002) suggested that in order to use the 
concept of CV strategically, the first task should be to identify key attributes of a product which 
are highly valued by the consumers, and the next task is to identify how consumers evaluate 
competing products, assuming that they make their purchase decisions with “value” as a key 
driver. This approach would then lead to the identification of key drivers of customer value. 
            This study will examine the diabetes market and identify value drivers for a new inhaled 
insulin product by measuring patients’ perceptions about the importance of different treatment 
goals, and the performance of inhaled insulin in comparison to other insulin products on these 
treatment goals. This analysis attempts to demonstrate the strategic value of understanding the 
components that drive consumer value.   
 
Diabetes Mellitus 
            Diabetes is one of the most prevalent chronic conditions in the United States, affecting 
almost 7.8% of the total population (23.6 million children and adults, out of which 7.9 million 
individuals are undiagnosed) (Diabetes statistics, 2007). The treatment of diabetes mellitus 
requires a versatile approach of both lifestyle modification (diet, exercise, weight control, 
smoking cessation) and pharmacological therapy. Usually the treatment for Type 2 diabetic 
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patients starts with lifestyle intervention, which, if failed to achieve the required hemoglobin 
glucose levels (HbA1c <7%), would be supplemented with a single oral agent. Further inability to 
maintain required glycemic control would require the addition of another oral agent with an 
alternate mechanism of action (Nathan, 2008). Beyond this point, if the patient is still facing 
problems with controlling his/her HbA1c, then the physician is left with an option of either 
adding a third or fourth oral insulin, or starting exogenous long-acting or short-acting insulin 
(Dahlof, 1999). Following an intensive insulin therapy regimen involving multiple daily 
subcutaneous injections has been shown to produce important clinical benefits in terms of 
controlling hyperglycemia (Clement et al., 2004). Despite the demonstrated clinical benefits 
associated with intensive insulin therapy, adherence is often observed to be poor among diabetic 
patients (Korytkowski, 2002). As a result of the progressive nature of the disease, most Type 2 
diabetic patients require exogenous insulin at some point in their lifetime to maintain the 
glycemic blood glucose levels (UK Prospective Diabetes Study Group, 1995). 
            Early initiation of the insulin therapy is found to be associated with reduced risk of 
developing micro and macro vascular complications in later stages of Type 2 diabetes (The 
Diabetes Control and Complications Trial Research Group, 1993; UK Prospective Diabetes 
Study (UKPDS) Group, 1998; Scarlett, Gray, Griffin, Olefsky, & Kolterman, 1982; Andrews et 
al., 1984; Garvey, Olefsky, Griffin, Hamman, & Kolterman, 1985). There are several reasons 
underlying the reluctance to start insulin therapy by patients, involving side effects of insulin 
therapy, like weight gain and risk of hypoglycemic events, progression to serious stage (prelude 
to death), failure of past treatment, expected pain from self injections and fear of complexity of 
the insulin regimen (Korytkowski, 2002). Therefore, insulin therapy might be well tolerated by 
some patients, while others may be less tolerable to the side effects or perceive it as 
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inconvenient.  Elimination of these barriers to insulin therapy might have a substantial impact in 
terms of achieving optimal glycemic control (Peyrot et al., 2005).  
            Diabetic patients often desire collaborative decision making with their health care 
providers and actively seek information about their conditions and available therapeutic 
alternatives. Patient preference for a medication can be simply defined as global impression of a 
given treatment with respect to its pros and cons (Dahlof, 2001). Greater understanding of the 
factors which influence patient preferences for different drug therapies may provide important 
guidance for physicians in making rational decisions for their patient (Dahlof, 1999). The key 
attributes of drug products that are often considered by physician and patient may vary by 
indication but generally include some combination of: safety, efficacy, side effects, tolerability, 
mode of administration, and onset of action (Dahlof, 2001; Mark & Swait, 2003).   
 
Research Objectives 
            A new inhaled insulin system is currently under development.  The arrival of a new 
insulin delivery system into the market will provide diabetic patients with another alternative for 
administering insulin, which is predominantly delivered by syringes and pens. A major 
advantage offered by inhaled insulin over traditional insulin products might be its added 
convenience. However, that needs to be empirically tested.   
            As lack of public appeal for Exubera (inhaled insulin by Pfizer launched in 2006) was 
considered to be the primary reason behind its removal from the market in 2007 (Pinto, Holiday-
Goodman, Black, & Lesch, 2009), it will be critical for the manufacturer of new inhaled insulin 
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to measure patients’ perceptions about the product and identify ways to differentiate the new 
insulin product from currently available short-acting insulin syringe/vials and pens. This leads us 
to the following research objectives: 
• To examine patients’ perceptions about current injectable insulin in comparison to inhaled 
insulin and to use these measures to predict their preferences for the new inhaled insulin 
product. This will help calculate the derived importance of product performance. 
• To explore differences between insulin users and non-insulin taking (naïve) diabetic patients 
in terms of value drivers for the new inhaled insulin product. 
            The specific aim of this study was to explore and develop strategic insights related to 
value drivers for inhaled insulin using the Strategic Value Driver Model (SVDM).  Specifically, 
this study examined the role of product attributes in the decision to purchase an insulin delivery 
system by identifying the most important attribute(s) driving the value of the new insulin 
product. The criticality of the product attributes and relative performance of three insulin 
delivery systems were evaluated based on economic and marketing theories.  
 
Significance 
            This study helped identify the most important product attributes that influence patients’ 
preferences for the new inhaled insulin. Furthermore, the results were used in developing the 
value drivers for the new inhaled insulin using SVDM and helped demonstrate the value of the 
SVDM method for evaluating product performance and developing marketing strategies. The 
results from this study will have the potential to assist pharmaceutical companies in developing 
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marketing and promotional plans for new products for diabetes. By identifying patients who 
would value a new product more, pharmaceutical companies can develop more effective 
promotional plans. This method can also be used for determining the value of other 
pharmaceutical products and help in pricing those products. If a new product’s performance is 
perceived to be better than its competitor is, it can better support a premium price compared to 
other products in the same market.  
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CHAPTER II – LITERATURE REVIEW 
 
“Customer value is a customer’s perceived preference for and evaluation of those product attributes, 
attribute performances, and consequences arising from use that facilitate (or block) achieving the 
customer’s goals and purposes in use situation”                            (Woodruff, 1997) 
 
The Concept of Value 
            A vague description of the concept of value was first based on philosophical views, but 
later the introduction of terms like “use value” and “exchange value” provided a better 
understanding of the term “value” (Woodall, 2003). In the 18th century, the utilitarian approach 
provided some explanation of how value-related choices could be made but was not of much use 
in explaining the decision-making process itself (Woodall, 2003). According to economists, 
choices made by customers are assumed to be based on utility maximization (Machina, 1987). 
According to this approach, consumers make decisions by selecting a product or service based 
on their assumption of gaining maximum utilities from that product or service.  
            Zeithaml (1988) suggested that perceived value could be regarded as an overall 
assessment of a product’s utility based on the perception of what is received and what is given in 
the whole process. Zeithaml also argued that some consumers perceive value when price is low, 
whereas others perceive greater value when there is a balance between quality and price. Cost 
plays an important role in patients’ decision making regarding adopting a new product; however, 
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cost is not equal to value since some consumers relate price to quality and may perceive more 
costly products to be higher in value than other available options.  
            Another concept of value was explored by Rokeach (1973), according to which every 
individual possesses a set of personal values that act as motivational forces in terms of guiding 
the individual through the decision making process. Since it is well known that every individual 
evaluates the utility gained in a different way, it could mean that every individual possesses a 
different set of values that motivates the decision-making process. Stern (1979) named those sets 
“internal drivers”, which makes these individuals express their choices in an entirely unique 
ways. Frondizi (1971) suggested that value differentiating characteristics may exist not only 
within individuals, but also within the objects. Various other authors suggested a similar 
explanation for value, like Heskett, Loveman, Sasser, & Schlesinger (1994), who claimed that 
“value drives customer satisfaction” and Hallowell (1996), who suggested that “satisfaction is 
the customer’s perception of the value received in a transaction or relationship”. 
            The literature on the concept of value is as broad and extensive in the fields of marketing, 
as it is in the field of economics and philosophy. In the marketing literature, Gale (1994), was the 
first one to quantify the concept of perceived value by mapping the rating scores of comparative 
products on the customers’ perceptions about product quality and price. He calculated customer 
value (market-perceived quality rating) using the formula: 
Customer Value = (Relative overall quality score * Quality weight) + (Relative price 
competitiveness score * Price weight).  
            Here, the relative overall quality score is the ratio of quality scores of comparative 
products for an attribute, and quality weight is the weight assigned to that attribute by the 
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customer. He suggested that the overall customer value should be more than 13⅓ percent in 
order to position the product in a superior value position (In other words, the overall market-
perceived ratio, MPR, should be greater than 1.133).  
            Buyers’ perceptions of value represent tradeoffs between quality and benefits they 
perceive in the product, relative to the sacrifices they perceived in terms of price they paid 
(Monroe, 1990). Woodruff defined customer value as a “customer’s perceived preference for and 
evaluation of those products attributes, attribute performances, and consequences arising from 
use that facilitate (or block) achieving the customer’s goals and purposes in use situations” 
(Woodruff, 1997).  
            Although the strength of a relationship between a customer and a product could be 
determined both by product attributes and the personal values of the customer (Rokeach values) 
(Rokeach, 1973), for the purpose of this study, we will restrict ourselves to the evaluation of 
product attributes. Frondizi (1971) called relevant product attributes “intrinsic values” which are 
different from the “extrinsic values” (which are associated with the use or exchange of a 
product). He also suggested that product attributes that are valued by customers becomes 
intrinsic values of those products.      
            Based on the explanations provided by various authors, Woodall explained five primary 
forms of value for the customer (Figure 1, page 14) (Woodall, 2003). He explained “Net VC” as 
a utilitarian perspective where customers try to determine the ratio of benefits and sacrifices, 
where more benefits would mean good VC. “Derived VC” is perceived by a customer only after 
experiencing the product or service (derived in nature). 
 
 Figure I:  Forms of “Derived VC”
 
 “Sale VC” is meant to be associated with reduction of sacrifices (in terms of reduced cost or 
effort) rather than increasing benefits. Woodall explained “Rational VC”
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Woodall suggested that this form of VC is ass
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Figure II: The Determination of Value (Kolassa, 2009)
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Overview of Methods Used to Determine Value of Pharmaceutical Products 
            Many decisions need to be individualized, especially when they involve choices between 
possible outcomes that may be viewed differently by patients. For situations like these, where a 
decision maker has to select from competing alternatives on the basis of product-related 
attributes, patient preference models are useful for understanding patient behavior and for 
subsequent development of new drug products (Bingham, Johnson, & Miller, 2001). Two broad 
approaches have usually been discussed in the literature:  
1. “Attitude” surveys usually involve ranking and/or rating of different products (Weiss & 
McHorney, 2007). In social psychology, “Attitude” is defined as “a psychological tendency 
that is expressed by evaluating a particular entity with some degree of favor or disfavor” 
(Eagly & Chaiken, 1996).  
2. “Preference” surveys supported by economic theory measure utility associated with the 
products.    
            Preference surveys are often used for measuring an individual’s value for health care 
goods and services. These surveys are utilized to derive utility values by methods like rating 
scales, time trade-off, and standard gamble. They have also been used in the forms of contingent 
valuation methods (CVM), conjoint analyses (Johansson, Torling, & Karlsson, 2004) and 
discrete choice experiments (de Bekker-Grob et al., 2008). CVM is often used for willingness to 
pay studies and cost benefit analyses. Whereas conjoint analysis is commonly used to determine 
how people value different components of a service or a product. One drawback to it is that it 
provides preferences for hypothetical combinations of product attributes and product selections 
that do not necessarily reflect the real nature of product selection. Although conjoint analysis can 
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provide relative measures for the importance of product attributes, this method provides limited 
information about the sources of perceived value of the product attributes and thus is unable to 
provide strategic insights of product preferences, which is a very important piece of information 
for product promotion teams (Park & Srinivasan, 1994).                
 
Strategic Value Driver Model (SVDM) 
            Drawing on the literature on value assessment, it can be proposed that the value of an 
individual product attribute is a function of the importance of an attribute, the product’s relative 
performance on that attribute compared to its competitor, and the level of unmet need for that 
attribute in the current market. Marketing strategies can be used to increase a product’s overall 
value on an attribute by increasing the importance of that attribute, increasing positive 
differentiation of the product on that attribute, or increasing awareness of the perceived unmet 
need.   
            For exploring the value of pharmaceutical product attributes in order to develop 
marketing strategies based on the exploration, it is important that a method be used that provides 
information about each component of value. For this project, the conceptual framework used is 
referred to as the Strategic Value Driver Model (SVDM) (Figure 3, page 18). This model is 
based on the theory of multi-attribute utility which states that utility is gained from the attribute 
or properties of a product or service rather than the product or service per se (Lancaster, 1966). 
Since value is linked to the utility associated with an attribute, the model measures perceptions 
related to treatment goals that express different utilities that would be associated with product 
attributes.   
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Figure III: Strategic Value Driver Model (SVDM) 
 
 
 
            SVDM suggests that the examination and development of value drivers for a new 
pharmaceutical drug starts with assessing the importance of product attributes, by asking patients 
to rate the importance (importance ratings) of each attribute.  This is followed by assessing how 
well the new pharmaceutical drug and other drug alternatives or currently-available drugs 
perform on each product attribute.   
            This approach allows one to explore both the stated and derived importance of each 
product attribute individually, which helps in developing strategic insights of how the value for a 
product is created.  Stated importance is measured by having patients rate the importance of each 
product attribute (Chu, 2002). Stated importance may not actually drive the product use since it 
does not account for the relative product performance on the attribute (or the level of unmet 
need).  The overall value of a product on an attribute is closely associated with its derived 
importance.  Derived importance is measured by the statistical correlation between differences in 
product attribute ratings (predictors) for the products and the intention to use that product 
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(criterion) (Hanson, 1992).  Logistic regression coefficients or the odds ratios are generally used 
to develop the derived importance for product attributes (Chu, 2002). Marketing strategies are 
developed through derived importance by examining the differentiation on an attribute and its 
pay off in terms of preference for the new product. If this association is not strong, it could be 
due to a lack of importance being placed on that attribute or the product’s poorly perceived 
performance (or performance rating) on that attribute. The SVDM approach provides marketing 
personnel with all the information needed to identify the most important drivers of potential use 
and to identify the components that marketing strategy can try to leverage to increase product 
use. 
            As stated in Chapter 1, this study examined the value drivers for new inhaled insulin for 
Type 2 diabetic patients. Therefore, the appropriate product attributes that were examined are 
categorized in four general groups:  
Safety: This category includes the measures of risks and/or side effects and weight gain 
associated with the use of insulin products (Cefalu, 2002; Peyrot et al., 2005). New inhaled 
insulin with reduced amount of risks or side effects might be perceived as more valuable than 
currently available treatment options – injectable insulin (syringes and pens).  
Convenience: The convenience of taking insulin could be defined in terms of social 
acceptability, ease of use and activity interference (Summers, Szeinbach, & Lenox, 2004). 
Taking insulin injections in front of others might be inconvenient and socially undesirable for 
some patients, whereas for others it might not be a problem at all (Testa & Simonson 2007). 
Previous research suggests that taking insulin injections is more inconvenient than inhaling 
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insulin (Testa & Simonson, 2007; Pinto et al., 2009; Rosenstock, Cappelleri, Bolinder, & Gerber, 
2004). 
Clinical efficacy: This is defined in terms of the clinical goals, time of onset of action and 
duration of action of the insulin. Usually one would expect the patients to be only concerned 
with cost and convenience of a medication, but studies have shown that some patients inquire 
about the clinical efficacy of a drug and consider it during evaluation (Weiss & McHorney, 
2007; Ferrari et al., 2005).  
Cost: Previous research suggests that patients’ out of pocket costs for their drugs influence their 
prescription fill behavior and product preferences (Dranitsaris, Elia-Pacitti, & Cottrell, 2004; 
Mahadevia et al., 2006). A study by Pinto et al., (2009) showed that the patients who were 
unsatisfied with their current diabetes therapy were ready to pay more for new inhaled insulin, if 
available.  
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CHAPTER III – RESEARCH METHODOLOGY 
 
Operationalization of Variables 
Independent variables 
            The four categories of product attributes: safety, convenience, clinical efficacy and cost, 
were examined using different descriptions or measures (Table I, page 25). These different 
measures were adapted from previous research that examined diabetic patients’ satisfaction with 
insulin treatment and perceptions about diabetes medication (Testa & Simonson 2007; Monahan, 
Lane, Hayes, McHorney, & Marrero, 2009; Anderson et al., 2004). The importance (or 
criticality) of each of these product attributes were examined by asking them to rate the 
importance of each measure on a Likert-type 7 point scale, (where 1 – “Not important at all” and 
7 – “Very important”). Following this rating exercise, patients were presented with product 
profiles of insulin syringes/vials, insulin pens and new inhaled insulin. Patients were then 
required to rate how well the new inhaled insulin and currently available injectable insulin 
(syringes and pens) performed on the same product attribute measures. A Likert-type 7 point 
scale where 1 would mean “the product performance is worst on this item” and 7 would mean 
“the product performance was best on this item,” was used to assess patients’ perceived 
performance ratings for the three products on the treatment goal measures. These ratings were 
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used to determine if inhaled insulin is “Worse than,” “Not differentiated” or “Better than” the 
injectable insulin.   
 
Table I: Product attributes and their respective descriptors/measures  
S. No. Treatment goals Construct 
1 Control blood sugar (glucose) levels to goal levels Efficacy 
2 Keeping your blood sugar levels stable (avoiding 
high and low blood sugar levels) 
Efficacy 
3 Fasting (morning before breakfast) blood sugar 
(glucose) levels to goal levels 
Efficacy 
4 Post-prandial (after meal) glucose levels to goal 
levels 
Efficacy 
5 Avoiding symptoms of low blood sugar or 
hypoglycemia (such as sweating, trembling, 
dizziness, blurred vision and fast heart beat) 
Safety 
6 Reducing the possible side effects of insulin 
medication, like allergic reactions and reactions at 
the injection site which may cause redness, 
swelling and itching 
Safety 
7 Minimizing weight gain from insulin therapy Safety 
8 Flexibility in time required between insulin dose 
and eating  
Convenience 
9 Minimizing the frequency of monitoring blood 
sugar (glucose) with finger-stick test 
Convenience 
10 Convenient for me to carry with me during the day Convenience 
11 Making it easy to take insulin in a public place 
(where people might see you) 
Convenience 
12 Reducing the pain or discomfort of taking insulin Convenience 
13 Making it easy to accurately measure the correct 
dose of insulin 
Convenience 
14 Selecting the best product I can afford Cost 
15 Selecting the products with the lowest out-of-
pocket cost  
Cost 
16 Selecting a product that I can afford Cost 
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Dependent variables 
            For the dependent variable, respondents were asked to select a preferred product among 
the syringe/vial, pen and inhaled insulin. Then they were asked to state their likelihood to use 
inhaled insulin if their doctor recommended it. The likelihood to use was examined using an 
ordinal 5-point scale where 5 meant “definitely would,” 4 - “probably would,” 3 - “not sure,” 2 - 
“probably would not,” and 1 - “definitely would not.” A re-assessment based on physicians’ 
recommendations was necessary as patients may not make a decision to switch to new inhaled 
insulin without their doctors’ recommendations or prescriptions (Freemantle et al., 2005).  
 
Product profile development 
            The product profiles were created to reduce the knowledge gap in insulin users and 
insulin naïve patients and also to educate them about the new inhaled insulin product. The 
readability of the profiles was close to 9th grade level and considered appropriate for internet 
users (Walsh & Volsko, 2008). Information under each product profile was presented in a similar 
format in terms of efficacy, dosing, side effects, storage, and out of pocket monthly cost of the 
products, so that patients can easily compare all three products. The clinical information for the 
product profiles was gathered from package inserts of relevant products and various patient 
friendly websites. The product profile can be viewed in Appendix B. 
 
Survey Instrument Development       
            Along with operationalized variables, the survey also collected disease-specific 
information which included length of diabetes (years), current therapy type (oral and/or insulin), 
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device used to administer insulin (needle/syringe or pen), number of oral anti-diabetic tablets and 
frequency of administering insulin per day. An item was included for insulin users to capture 
their satisfaction and the level of pain experienced with their current insulin products. 
Demographic information (including weight and height for BMI calculation) was collected 
towards the end of the survey. The survey instrument can be viewed in Appendix A. 
 
Data collection and Study sample 
            A cross-sectional, internet-based, self-administered survey was used to collect the data.  
The survey was programmed using Qualtrics, a web-based tool used for designing and 
distribution of the survey over the Internet. Research participants were recruited from a national 
panel of diabetic patients provided by a market research consulting firm. A web-based survey 
was conducted as it allows rapid data collection from a widely dispersed and large sample 
(Evans & Mathur, 2005).  
 
Study Sample 
            Type 2 diabetic patients were included in this study since patients with Type 1 diabetes 
constitute a small percentage of all diabetics, and a collection of a significant number of 
respondents with Type 1 diabetes would have increased the recruitment times and costs of data 
collection. Since it was of interest to see how patients naïve to insulin therapy would behave in 
comparison to those who are already taking insulin, this study used quota sampling to ensure a 
roughly equal split between: 
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1. Type 2 diabetic patients who were taking injectable insulin, either alone or with oral anti-
diabetes drug(s), via syringes or pens, and 
2. Type 2 diabetic patients, naïve to insulin. This group of patients was on at least 2 oral anti-
diabetic drugs.  
            The reason for including Type 2 diabetic patients naïve to insulin therapy was that they 
might face a situation in the near future (which was made sure by controlling the severity of the 
disease, by selecting the patients who were on at least 2 oral anti-diabetic drugs) where, their 
HbA1c will not be controlled by oral medications, and their physicians may recommend starting 
insulin therapy. And some patients may also be in stages where their doctors may have 
considered starting them on insulin therapy.  
            As the patients are at different stages of diabetes, (insulin naïve and insulin taking), their 
purposes for evaluating new inhaled insulin will also be different. Insulin-taking patients might 
consider the new product as replacements for their current products whereas insulin naïve 
patients may consider it for adopting a new therapy all together.  
            Based on previous studies that examined diabetic patients’ preferences for diabetes 
products (e.g., Pinto et al., 2009) and considering the length of the survey, a total sample size of 
483 was collected for this study.  
 
Pretest  
            The survey was pre-tested in a two-step process. In the first step, the survey was given to 
Four trained diabetes educators (in the Department of Pharmacy Practice at the University of 
32 
 
Mississippi) to examine the level of understanding of the survey and clarity of the product 
profiles. Based on their input and after making appropriate changes, the survey was then tested 
using a convenience sample of staff members at the University of Mississippi with diabetes.  
Ultimately, the face and content validity of the survey was evaluated by Pharmacy 
Administration faculty and graduate students at the University of Mississippi. During these pre-
tests, the approximate time taken to complete the survey and reading difficulty level were also 
examined. Appropriate revisions to the questionnaire were conducted after the pretests.  
 
Analysis Plan 
            Data was analyzed using IBM SPSS®. Demographic characteristics and descriptive 
statistics were generated to describe the study sample. Reliability of the measures used to assess 
product attribute goals were assessed using Cronbach’s alpha and item-to-total correlation 
analysis. All statistical tests were 2-tailed, and the tests of significance were conducted at 0.05 
level of significance. The specific analysis planned for meeting each of the research objectives 
are described in the following sections.   
 
Objective 1: To examine patients’ perceptions about current injectable insulin in comparison to 
inhaled insulin, and to use these measures to predict their preference for the new inhaled insulin 
product.  
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            The derived importance of differences in product perceptions was examined using both 
univariate and multivariable analysis. Two difference-scores for each product attribute measure 
were computed by subtracting (1) the rating for injectable insulin - syringe/vials from the rating 
for inhaled insulin and (2) rating of injectable insulin - pen devices from the rating for inhaled 
insulin on that product attribute measure.  This gave two difference-score variables for each of 
the product attribute measures: clinical efficacy, convenience, safety and cost.   
            The difference score variables were then used to develop a summated-scale score for 
each product attribute (e.g., using the 3 difference-score efficacy measures we developed an 
overall efficacy summated-scale score).  As a result of this, four overall summated-scale score 
variables, one for each product attribute, were created for further analyses.  The summated-scale 
score variables were then converted into a categorical variable using the following criteria.  If the 
summated-scale value was greater than 0, then the scale was defined as “Inhaled insulin is better 
than injectable insulin.” If the value was less than 0, then it was defined as “Inhaled insulin is 
worse than injectable insulin.” If the value was equal to 0, then it was defined as “Inhaled insulin 
is not differentiated injectable insulin.” 
Univariate tests - Cross-tabs and chi-square statistics were used to examine the relationship 
between the calculated categorical summated-scale score variables and the most preferred 
product, which was also categorized into two levels –“Inhaled insulin” (if inhaled insulin is 
selected out of all the options) and “Others” (if insulin needle/syringe, insulin pen, or no 
preference, will take whatever the doctor prescribes is selected).   
Multivariate tests - Logistic regression was used to identify the strongest overall predictors of 
preference for inhaled insulin. The categorical measure of preference for inhaled insulin was 
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used as the dependent variable.  The independent variables were the categorical summated-scale 
score variables for the performance on four product attributes. 
 
Objective 2: To explore differences in insulin users and insulin naïve (not taking insulin) diabetic 
patients in terms of value drivers for a new inhaled insulin product. 
 
            The same univariate and multivariate analyses conducted for objective 1 was re-run to 
answer this question.  However, these analyses were conducted separately for insulin naïve and 
insulin-taking patients. 
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CHAPTER IV – RESULTS 
 
            Data was collected with the help of a market research vendor, e-Rewards. The sampling 
frame for this study included self-reported Type 2 diabetic patients who were members of a 
diabetic panel maintained by e-Rewards (which included 45,408 Type 2 diabetic patients). The 
survey invitation web link that was provided to e-Rewards, was used to invite a sample of 
diabetic patients. 1,493 patients accepted the invitation and responded to the survey, out of which 
516 were eligible and participated in the study. After excluding the patients (N=33) who did not 
differentiate between any of the insulin products and marked “Do not have sufficient 
information” on all product performance items, a sample of 483 patients was used for the 
analysis. It was assumed that if the patients had not read the entire product profiles, they would 
not be able to differentiate in between the products.   
            Data was collected over a span of six days, November, 16th through November, 21st 2010. 
Table II depicts the number of patients that responded each day. For the first two days, fewer 
people were invited as part of a soft launch in order to ensure proper working of the logic of 
branching and quotas. The raw data was downloaded from the Qualtrics software in IBM SPSS 
format. The final dataset was visually inspected for out-of-range and missing values. 
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Table II: Schedule of data collection 
Date Completed responses Cumulative responses 
Tuesday, 16th November 2010 7 7 
Wednesday, 17th November 2010 31 38 
Thursday, 18th November 2010 96 134 
Friday, 19th November 2010 255 389 
Saturday, 20th November 2010 88 477 
Sunday, 21th November 2010 39 516 
 
Sample description 
            A total of 482 responses were used for the final analysis, out of which 47.1% (n=227) 
were using insulin (either with or without diet, exercise and oral anti-diabetic pills) to control 
diabetes, and the remaining 52.9% (n=255) were insulin naïve (either with or without diet, 
exercise). The two groups were similar across all demographic variables except for the annual 
household income. A higher percentage of insulin naïve patients had income over $75,000 in 
comparison to the insulin-using patients (41.56% vs. 29.51%, respectively; χ2=12.586, df=5, p = 
0.028). Respondents had an average age of 58 years with a slight over-representation of males 
(54.2% - males, 45.8% - females). The sample was fairly educated with 54.3% of respondents 
having at least a Bachelor’s degree (four-year degree). Of the respondents, 51% mentioned that 
they never smoked, whereas 39.7% reported themselves as ex-smokers. The respondents were 
asked to report their weights and heights, which were later used to calculate their BMI. The 
calculated BMI was then divided into 3 categories – normal weight (BMI <25), overweight (BMI 
= 25-29.9), and obese (BMI >=30) (Heisler, Kieffer, Piette, Vijan, & Spencer, 2005). The 
majority (70.9%) of the respondents were found to be in the obese category. A summary of 
demographic information is presented in Table III. 
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Table III: Baseline characteristics of the sample 
 Insulin naïve Insulin taking Total 
N % N % N % 
Sample 255 52.9% 227 47.1% 482  
Gender 
Male 130 54.2% 110 51.6% 240 53% 
Female 110 45.8% 103 48.4% 213 47% 
Age 
Up to 45 years 24 10% 25 11.8% 49 10.8% 
45-65 159 66.3% 137 64.6% 296 65.5% 
65 and above 57 23.8% 50 23.6% 107 23.7% 
Ethnicity 
Caucasian/White 211 87.9% 187 87.8% 398 87.9% 
Other 29 12.1% 26 12.2% 55 12.1% 
Annual household income* 
Up to $ 24,999 22 9.2% 16 7.5% 38 8.4% 
$ 25,000-49,999 41 17.1% 39 18.3% 80 17.7% 
$ 50,000-74,999 45 18.8% 60 28.2% 105 23.2% 
$ 75,000-99,999 41 17.1% 33 15.5% 74 16.3% 
$ 100,000 and above 65 27.1% 34 16.0% 99 21.9% 
Do not wish to answer 26 10.8% 31 14.6% 57 12.6% 
Highest level of education 
High school diploma 31 12.9% 23 10.8% 54 11.9% 
Some college 51 21.3% 51 26.3% 107 23.6% 
Associate’s degree  28 11.7% 20 9.4% 48 10.6% 
Bachelor’s degree 68 28.3% 69 32.4% 137 30.2% 
Master’s degree 47 19.6% 32 15.0% 79 17.4% 
Doctoral degree 15 6.3% 13 6.1% 28 6.2% 
Smoking status 
Non-smoker 124 51.7% 107 50.2% 231 51.0% 
Regular smoker 13 5.4% 15 7.0% 28 6.2% 
Occasional smoker 8 3.3% 6 2.8% 14 3.1% 
Ex-smoker 95 39.6% 85 39.9% 180 39.7% 
BMI 
Normal weight (<25) 13 7.9% 12 8.1% 25 8.0% 
Overweight (25-29.9) 36 22.0% 30 20.1% 66 21.1% 
Obese (≥30) 115 70.1% 107 71.8% 222 70.9% 
*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the 
annual household incomes of two groups at p < 0.05 significance level. 
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            Nearly half (45.2%) of the respondents reported their diabetes to be under control with 
HbA1c values under 7%. 91.5% had some kind of insurance that paid for their diabetic 
medications, whereas fewer (69.5%) had insurance coverage for insulin devices. The average 
duration of diabetes for the entire sample was 11.24 years. Table IV represents the summary of 
disease specific characteristics. Insulin naïve patients were different from insulin users in terms 
of reported HbA1c test values, with insulin naïve patients having good glycemic controls 
(χ2=20.632, df=4, p < 0.001). In terms of insurance for insulin devices, as expected, a higher 
percentage of insulin users had it in comparison to insulin naïve patients (χ2=77.863, df=2, p <. 
001). Also, the number of years with diabetes was higher in insulin users (χ2=34.348, df=4, p < 
0. 001). 
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Table IV: Disease specific characteristics 
 Insulin naïve Insulin taking Total  
 N % N % N % 
Sample 255 52.9% 227 47.1% 482  
HbA1c test value* 
<7% 129 50.6% 89 39.2% 218 45.2% 
7-7.9% 71 27.8% 59 26.0% 130 27.0% 
8-8.9% 21 8.2% 35 15.4% 56 11.6% 
≥9% 9 3.5% 27 7.4% 36 7.4% 
Don’t know 25 9.8% 17 11.9% 42 8.7% 
Target HbA1c value*  
<5% 19 7.5% 22 9.6% 41 8.5% 
<6% 107 42.0% 76 33.3% 183 37.9% 
<7% 123 48.2% 114 50.0% 237 49.1% 
<9% 6 2.4% 16 7.0% 22 4.6% 
HbA1c assessment 
Correct 84 32.9% 83 36.4% 167 34.6% 
Incorrect 171 67.1% 145 63.6% 316 65.4% 
Insurance of diabetes medication 
Yes 234 91.8% 208 91.2% 442 91.5% 
No  21 8.2% 20 8.8% 41 8.5% 
Insurance of insulin devices* 
Yes 137 53.7% 199 87.3% 336 69.6% 
No  53 20.8% 27 11.8% 80 16.6% 
Do not know 65 25.5% 2 0.9% 67 13.9% 
Number of years with diabetes* 
Up to 2 years 15 5.9% 8 3.5% 23 4.8% 
3-5 72 28.2% 32 14.0% 104 21.5% 
6-10 82 32.2% 69 30.3% 151 31.4% 
11-15 58 22.7% 51 22.4% 109 22.6% 
16 and above 28 11.0% 68 29.8% 95 19.9% 
*Comparisons based upon the Pearson chi-square statistics for column portions showed significant differences in the 
HbA1c test values, target HbA1c, insurance for medical devices and number of years with diabetes in two groups at 
p < 0.05 significance level. 
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Clinical knowledge of diabetes 
            Before looking into the importance that diabetic patients placed on various treatment 
goals, their understandings of some clinical aspects were captured using a 3-item scale (Table 
V). The majority of Type 2 diabetic patients had a good knowledge of HbA1c tests. A higher 
percentage of patients were aware of fasting blood glucose levels (80.5% marked high 
knowledge on a 7-point scale) in comparison to prandial blood glucose levels (69%). In general, 
the patients had a good understanding of the clinical aspects of diabetes.  
 
Table V: Understanding of clinical aspects of diabetes 
Items  Mean ± SD* Percentage of patients in top 
2 boxes (i.e., rated 6 & 7)** 
HbA1c test and its meaning for 
a person with diabetes 
6.43 ± 0.92 442 (91.5%) 
Achieving the required fasting 
blood glucose levels 
6.07 ± 1.07 389 (80.5%) 
Achieving the required post-
prandial blood glucose levels 
5.86 ± 1.16 334 (69.1%) 
*Mean ± SD (range) importance ratings out of 7. Where 1= Not at all important, and 7 = Extremely important. 
**represents the patients who marked importance of an item to be very high (i.e., marked 6 or 7 on a 7 point scale).  
 
            Furthermore, respondents’ clinical knowledge of HbA1c was checked with the help of 
their self-evaluations of their levels of diabetes control. It was assessed by asking the results of 
their most recent HbA1c test values and the state of their diabetes based on those values (Heisler 
et al., 2005). Based on this information, a dichotomous variable was created (“Yes” – correct 
assessment, “No” – wrong assessment), which served as a proxy for the respondents’ self-
evaluations and understanding of clinical aspects of diabetes. 34.6% (n = 167) of the diabetic 
patients correctly assessed the states of their diabetes based on HbA1c test values (Table IV).  
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Medication use pattern 
            As per the eligibility criteria for this study, patients were required to be on insulin therapy 
or a minimum number of 2 OADs. Every patient was found to be on some form of a combination 
of diet and exercise, OADs, insulin injections and/or non insulin injections like Byetta and 
Victoza. 35.4% of the diabetic patients were on a combination of diet and exercise, and OADs 
whereas 18.6% were taking OADs and insulin along with diet and exercise. Only 7.6% were 
taking insulin along with diet and exercise. Overall, 400 diabetic patients (82.9%) were taking at 
least 2 oral anti-diabetic medications (either alone or in combination with diet/exercise and/or 
insulin therapy), whereas, about 68.6% (n = 331) of the diabetic patients mentioned that they 
were on diet and exercise (either along with OADs and/or insulin injections and/or non-insulin 
injections like Byetta and Victoza) (Table VI).  
             As far as the distribution of the type of OAD was concerned, a somewhat similar pattern 
was observed between insulin users and insulin naïve groups. Out of all the drug classes, the uses 
of Biguanides (67.2%), Sulfonylureas (49%), and Thiazolidinediones (27.2%) were found to be 
most prevalent. The information on the use of pen, syringe/injections for administering insulin 
was also collected and is displayed in Table VI. In this sample, we found more pen users in 
comparison to syringe/vial users (23.2% vs. 18.4%, exclusive of “both pen and syringe 
category”). 
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Table VI: Current treatment regimen 
 Insulin naïve Insulin taking Total 
N % N % N % 
Sample 255 52.9% 227 47.1% 482 100% 
Diet and exercise 188 73.7% 143 63% 331 68.7% 
Oral anti-diabetics 255 100% 145 63.9% 400 83.0% 
Insulin injections - - 227 100% 227 47.1% 
Insulin pump - - 3 1.3% 3 0.6% 
Non-insulin injections 24 9.4% 19 8.4% 43 8.9% 
Oral anti-diabetics 
Sulfonylureas 175 68.6% 61 26.9% 236 49% 
Meglitinides 16 6.3% 8 3.5% 24 5% 
Biguanides 226 88.6% 98 43.2% 324 67.2% 
Thiazolidinediones 105 41.2% 26 11.5% 131 27.2% 
Alpa-glucosidase 
inhibitors 
2 0.8% 3 1.3% 5 1.0% 
DPP-4 inhibitors 53 20.8% 19 8.4% 72 14.9% 
Insulin injection device 
Insulin pens only  - - 112 49.3% 112 23.2% 
Syringes only  - - 89 39.2% 89 18.4% 
Both pen and syringe - - 26 11.5% 26 5.4% 
 
Reliability 
            The reliability of the product attributes (i.e., clinical efficacy, safety, convenience, and 
cost) and understanding of clinical aspects of diabetes was assessed by calculating Cronbach’s 
alpha for each construct (Table VII). All the constructs had a Cronbach’s alpha well over 0.7 and 
had item-to-total correlations (correlations of individual items to the summated score of the 
scale) exceeding 0.5, indicating high internal consistency among the constructs. The mean inter-
item correlation (correlations of individual items to other items on the scale) also exceeded 0.3 
for all the five constructs, further assuring the reliability of the scales (Hair et al., 2006; 
Cronbach, 1951). 
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Table VII: Summary of scale properties 
Scale Number of items Cronbach’s alpha 
Clinical Efficacy 4 0.880 
Safety 3 0.787 
Convenience 6 0.868 
Cost 3 0.918 
Understanding of clinical 
aspects of diabetes 
3 0.873 
 
Satisfaction with current insulin product 
            Diabetic patients were asked to report the level of satisfaction with the insulin product 
they were currently using, on a 5-point Likert type scale (“Very dissatisfied,” “Somewhat 
satisfied,” “Not sure,” “Somewhat satisfied,” “Very satisfied”). Due to lower cell numbers, 
satisfaction was converted into a dichotomous variable – “Yes” (for “Somewhat satisfied” and 
“Very satisfied”), “No” (for “Very dissatisfied,” “Somewhat dissatisfied,” and “Not sure”). 
Overall, 77.6% (N=120, total number of insulin pen users) of patients were satisfied with pens, 
and 55.8% (N=106, total number of insulin syringe/vial users) of patients were satisfied with 
syringes.  Cross-tab results for satisfaction and HbA1c levels can be seen in Table VIII. The 
relationship between HbA1c values and satisfaction with current insulin product used was 
examined with the help of Pearson Chi-square tests. Although, with the increase in HbA1c 
values (uncontrolled HbA1c levels), a fewer percentage of patients were satisfied with 
syringe/vial insulin, but the effect was not statistically significant.  
 
44 
 
Table VIII: Association of HbA1c values with preference for inhaled insulin and 
satisfaction with current insulin product use 
HbA1c 
value 
Satisfaction with pen Satisfaction with 
syringe/vial 
Preference for inhaled 
insulin 
No Yes No Yes No Yes 
<7% 7(13.5%) 45(86.5%) 14(28.6%) 35(71.4%) 72(80.0%) 18(20.0%) 
7-7.9% 12(32.4%) 25(67.6%) 10(40.0%) 15(60.0%) 41(69.5%) 18(30.5%) 
>8% 9(25.0%) 27(75.0%) 15(46.9%) 17(53.1%) 48(77.4%) 14(22.6%) 
 
  
            When the effect of satisfaction with current insulin product used was examined on the 
preference for inhaled insulin, a higher percentage of unsatisfied patients seemed to prefer 
inhaled insulin. There was a statistically significant relationship between satisfaction with 
syringe/vial insulin and the preference for inhaled insulin (χ2=13.192, df=1, p <. 001). A higher 
percentage of patients not satisfied in comparison to those who were satisfied with their current 
insulin products, preferred inhaled insulin (Table IX). These results were found to be in 
agreement with previous findings, where patients with high HbA1c values (as a result of poor 
adherence with insulin therapy) were less satisfied (Anderson et al., 2004). 
 
Table IX: The effect of satisfaction with current insulin product used on preference for 
inhaled insulin 
Satisfaction  Preference for inhaled insulin 
No Yes 
Syringe/vial insulin* No 29(63.0%) 17(37.0%) 
Yes 61(91.0%) 6(9.0%) 
Pen insulin No 21(67.7%) 10(32.3%) 
Yes 82(77.4%) 24(22.6%) 
*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the 
preferences for inhaled insulin with the level of satisfaction with syringe/vial insulin at p < 0.001 significance level. 
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Product attribute measures 
            The product attribute measures were explored in a 2-step process. First, the patients were 
asked to rate the importance of each item under four product attributes. Second, the patients were 
asked to rate the performances of three insulin products on those items after reading product 
profiles. Table X shows the importance of product attributes from the perspective of Type 2 
diabetic patients, captured in the form of importance of achieving various goals of the insulin 
therapy. Since the product attribute importance means were very high (along with small standard 
deviations), the 7-point Likert type scale was also explored as a dichotomous variable (“Very 
high importance” – importance rating 6 and above, and “Medium importance” – importance 
rating below 6).  
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Table X: Mean importance ratings for perceived importance of various product attribute 
measures  
Product attribute items  
Average importance 
ratings (Std Dev)* 
Percentage of patients in 
top 2 boxes (6 & 7)** 
Control blood sugar levels to goal levels 6.38 (0.90) 406 (91.9%) 
Keeping your blood sugar levels stable 6.34 (0.92) 394 (89.4%) 
Fasting blood sugar levels to goal levels 5.96 (1.05) 338 (75.7%) 
Post-prandial glucose levels to goal 
levels 
5.81 (1.08) 304 (67.5%) 
Clinical Efficacy 6.12 (0.85)  
Avoiding Symptoms of low blood sugar 
or hypoglycemia 
6.36 (1.00) 396 (89.6%) 
Reducing the possible side effects of 
insulin medication, like allergic 
reactions 
6.00 (1.16) 338 (75.9%) 
Minimizing weight gain from insulin 
therapy 
6.16 (1.07) 359 (80.5%) 
Safety 6.17 (0.90)  
Flexibility in time required between 
insulin dose and eating 
5.71 (1.15) 276 (62.3%) 
Minimizing the frequency of monitoring 
blood sugar with finger-stick test 
5.56 (1.22) 252 (57.1%) 
Convenient for me to carry with me 
during the day 
5.74 (1.30) 298 (68.3%) 
Making it easy to take insulin in a public 
place 
5.39 (1.49) 244 (56.1%) 
Reducing the pain or discomfort of 
taking insulin 
5.58 (1.39) 263 (58.8%) 
Making it easy to accurately measure the 
correct dose of insulin 
6.19 (1.08) 374 (83.2%) 
Convenience 5.70 (0.99)  
Selecting the best product I can afford 5.92 (1.34) 340 (76.6%) 
Selecting the products with the lowest 
out-of-pocket cost 
5.53 (1.53) 264 (59.8%) 
Selecting a product that I can afford 5.79 (1.46) 317 (70.6%) 
Cost 5.75 (1.34)  
*Mean ± SD (range) importance ratings on a 7 point Likert type scale.  
**Represents the percentage of patients who reported an item to be of very high importance (i.e., marked 6 or 7 on a 
7-point scale).  
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             The majority of items for clinical efficacy and safety had a high mean importance, which 
shows that diabetic patients consider clinical attributes (efficacy and safety of drug products) to 
be more important in comparison to convenience and cost of the insulin product. “Controlling 
blood sugar levels to goal levels” was reported to be the most important factor with a mean of 
6.38 (on a 7-point scale), whereas “Making it easy to take insulin in a public place” was found to 
be least important item with a mean of 5.39. 
            After examining the importance of product attributes, the performances of inhaled 
insulin, syringe/vial insulin and pen insulin were explored on the same product attributes. Table 
XI depicts the performance of insulin products on various treatment goals (categorized under 
four product attributes). Overall, inhaled insulin was perceived to perform best under clinical 
efficacy, safety, and convenience, followed by pen insulin and finally syringe/vial insulin, 
whereas, for the cost of items, an opposite trend was seen with syringe/vial insulin considered 
least expensive, followed by pen insulin and inhaled insulin. 
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Table XI: Performance of inhaled, pen, and syringe insulin on product attribute measures 
Product attributes 
Inhaled 
insulin* 
Pen 
insulin* 
Syringe 
insulin* 
Clinical 
efficacy 
Control blood sugar levels to goal 
levels 
6.29 
(1.626) 
6.06 
(1.147) 
5.66 
(1.578) 
Keeping your blood sugar levels stable 
6.24 
(1.562) 
5.66 
(1.368) 
5.52 
(1.578) 
Fasting blood sugar levels to goal 
levels 
6.43 
(1.533) 
6.18 
(1.417) 
6.01 
(1.634) 
Post-prandial glucose levels to goal 
levels 
6.39 
(1.617) 
6.16 
(1.424) 
6.05 
(1.590) 
Safety  
Avoiding Symptoms of low blood 
sugar or hypoglycemia 
6.05 
(1.776) 
5.56 
(1.410) 
5.29 
(1.613) 
Reducing the possible side effects of 
insulin medication, like allergic 
reactions 
6.44 
(1.319) 
5.13 
(1.698) 
4.74 
(1.869) 
Minimizing weight gain from insulin 
therapy 
5.50 
(2.090) 
5.09 
(2.005) 
4.93 
(2.054) 
Convenience 
Flexibility in time required between 
insulin dose and eating 
6.16 
(1.536) 
5.52 
(1.482) 
5.12 
(1.709) 
Minimizing the frequency of 
monitoring blood sugar with finger-
stick test 
6.24 
(1.752) 
5.88 
(1.728) 
5.60 
(1.940) 
Convenient for me to carry with me 
during the day 
6.42 
(1.193) 
6.02 
(1.193) 
3.86 
(1.957) 
Making it easy to take insulin in a 
public place  
6.42 
(1.230) 
5.45 
(1.398) 
3.58 
(1.843) 
Reducing the pain or discomfort of 
taking insulin 
6.60 
(1.092) 
4.93 
(1.584) 
3.83 
(1.915) 
Making it easy to accurately measure 
the correct dose of insulin 
6.29 
(1.466) 
6.31 
(1.058) 
4.87 
(1.804) 
Cost  
Selecting the best product I can afford 
5.30 
(1.920) 
5.79 
(1.439) 
5.75 
(1.592) 
Selecting the products with the lowest 
out-of-pocket costs 
4.64 
(2.061) 
5.86 
(1.394) 
6.12 
(1.339) 
Selecting a product that I can afford 
5.17 
(1.967) 
6.01 
(1.363) 
6.12 
(1.318) 
*Mean ± SD (range) importance ratings out of 7.  
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            The summated scale score variables were derived from product performance ratings 
based on the criteria described in Chapter 3, page 23. Table XII shows the percentage 
distribution of diabetic patients who defined inhaled insulin to be worse, undifferentiated, or 
better in comparison to pen insulin and syringe/vial insulin. A similar trend was observed in both 
the comparisons, with inhaled insulin being perceived better in comparison to pen and 
syringe/vial insulin by the majority of diabetic patients (under efficacy, safety and convenience). 
Even though pen insulin is thought to be a convenient method of taking insulin, inhaled insulin 
was perceived to be better than pen insulin by 78.8% of patients. As far as cost was concerned, 
inhaled insulin was perceived to be worse than both pen and syringe/vial insulin by 57.3% and 
56.2% of patients, respectively. It was interesting to note that a group of patients still perceived 
inhaled insulin to be better in cost (20.7% in comparison to pen insulin and 21.45% in 
comparison to syringe/vial insulin). As expected, the majority of patients (87% for syringe vs. 
78.9% for pen) perceived inhaled insulin to be better than syringe insulin and pen insulin in 
convenience. 
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Table XII: Cross-tabs results of product differentiation on product attributes 
  %  of patients 
Product attributes Inhaled compared to 
pen 
Inhaled compared to 
needle/syringe 
 Worse 18.8% 17.8% 
Clinical Efficacy  Not differentiated 22.6% 20.5% 
   Better  58.6% 61.7% 
 Worse 15.1% 13.7% 
Safety  Not differentiated 19.0% 18.4% 
 Better  65.8% 67.9% 
 Worse 11.6% 4.1% 
Convenience  Not differentiated 9.5% 8.9% 
 Better  78.9% 87.0% 
 Worse 57.1% 56.1% 
Cost  Not differentiated 22.2% 22.4% 
 Better  20.7% 21.5% 
 
Product Preferences 
            The preferences for insulin products in diabetic patients were captured at two levels. 
First, the patients were asked to imagine if there was no difference in the out-of-pocket costs of 
all three products; and, in the second situation, they were asked to consider the out-of-pocket 
costs of the products as per their personal insurance coverages and information provided to them. 
The product preferences are depicted in Table XIII. 
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Table XIII: Descriptive for preferences of insulin products  
 Insulin naïve Insulin users Total 
 N % N % N % 
Sample 255 52.9% 227 47.1% 482  
Product choice with no difference in cost* 
Insulin needle 2 0.8% 18 7.9% 20 4.1% 
Insulin pen 52 20.4% 70 30.7% 122 25.3% 
Inhaled insulin 178 69.8% 100 43.9% 278 57.6% 
No preference, will take 
whatever the doctor 
prescribes 
23 9.0% 40 17.5% 63 13.0% 
Actual product choice (considering cost difference)* 
Insulin needle 8 3.1% 47 20.6% 55 11.4% 
Insulin pen 92 36.1% 86 37.7% 178 36.9% 
Inhaled insulin 123 48.2% 52 22.8% 175 36.2% 
No preference, will take 
whatever the doctor 
prescribes 
32 12.5% 43 18.9% 75 15.5% 
Likelihood to use inhaled insulin on doctors recommendation* 
Very unlikely 5 2.0% 15 6.6% 20 4.1% 
Unlikely 3 1.2% 9 3.9% 12 2.5% 
Undecided 24 9.4% 41 18.0% 65 13.5% 
Likely 73 28.6% 52 22.8% 125 25.9% 
Very likely 150 58.8% 111 48.7% 261 54.0% 
Ask doctor for inhaled insulin* 
Very unlikely 3 1.2% 10 4.4% 13 2.7% 
Unlikely 8 3.1% 31 13.6% 39 8.1% 
Undecided 76 29.8% 62 27.2% 138 28.6% 
Likely 98 38.4% 85 37.3% 183 37.9% 
Very likely 70 27.5% 40 17.5% 110 22.8% 
*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the 
preferences for inhaled insulin among two groups at  p < 0.001 significance level. 
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            Results indicate that inhaled insulin was the most preferred product (57.5%), when 
patients were told to assume no difference in the out-of-pocket costs of the products. The product 
preferences changed when the patients were asked to consider their monthly out-of-pocket costs 
of the products, and insulin pen and inhaled insulin were found to be equally preferred products 
(with 36.9% and 36.3%, respectively). When the two groups were compared for product choice 
with no differences in cost, a higher percentage of insulin naïve patients than insulin users 
preferred inhaled insulin. Even after considering the out-of-pocket costs, preference for inhaled 
insulin was high among insulin naïve patients (48.2% insulin naïve vs. 22.8% insulin users). 
Doctors’ recommendations seemed to influence patients’ decisions in both the groups and 
overall, 60% of the patients were likely to ask their doctors to prescribe inhaled insulin.  
 
Examination of research objectives 
Objective 1: To examine patients’ perceptions about current injectable insulin in comparison to 
inhaled insulin and to use these measures to predict their preferences for the new inhaled insulin 
product.  
 
Product attributes variables, and preference for inhaled insulin 
            After the summation of importance ratings for product attribute items, a mean importance 
score for each attribute was created. Then the summated-scale scores were converted into a 
dichotomous variable using the criteria: “Very high importance” – importance rating 6 and above 
and “Medium importance” – importance rating below 6. Table XIV shows the results of 
univariate logistic regression models, which were run in order to see if the patients who marked 
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an attribute to be of “Very high importance” or “Medium importance”, were different from each 
other in terms of their preferences for inhaled insulin.   
 
Table XIV: Results of univariate logistic regression between perceived importance of 
product attribute measures and preferences for inhaled insulin 
Product attributes β Sig. OR 95% C.I. for OR 
    Lower Upper 
Clinical Efficacy .207 .33 1.23 .81 1.868 
Safety .789 .001 2.202 1.373 3.531 
Convenience 0.486 .011 1.626 1.119 2.363 
Cost .156 .424 1.169 .797 1.714 
 
            Importance placed on safety (Wald = 10.717, p = 0.001) and convenience (Wald = 6.49, 
p = 0.011) significantly predicted the preference for inhaled insulin. Based on odds ratio, the 
patients were 2.2 and 1.63 times more likely to prefer inhaled insulin if they marked safety and 
convenience of a product to be of high importance rather than medium importance.  
            A Pearson chi-square test was run to check the relationship of preference for inhaled 
insulin with summated-scale score variables for the performances (on product attributes) of 
inhaled versus competitive products. The performance comparison of inhaled insulin and pen 
insulin on efficacy, safety and convenience had a statistically significant relationship with the 
preference for inhaled insulin; whereas, for a performance comparison of inhaled and 
syringe/vial insulin, all four product attributes had a statistically significant relationship with the 
preference for inhaled insulin. Table XV provides the percentage of patients under “worse,” “not 
differentiated,” and “better” categories for comparison of product performance that preferred 
inhaled insulin. Except for the cost attribute, the majority of the patients prefer inhaled insulin 
only if they perceived inhaled insulin to perform better than its competitors. This effect is most 
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pronounced in the case of convenience, where the patients prefer inhaled insulin only if they 
perceived it to be more convenient than its competitors.    
 
Table XV:  Percent of patients preferring inhaled insulin by categories “Worse,” “Not 
differentiated,” and “Better” for performance on product attributes 
Product attributes 
Inhaled insulin vs. pen insulin Inhaled vs. syringe/vial insulin 
Worse Not differentiate Better Worse Not differentiate Better 
Clinical Efficacy  2.9% 7.5% 25.9% 4.1% 6.2% 25.9% 
Safety  2.5% 5.0% 28.8% 2.5% 4.1% 29.6% 
Convenience  0.8% 1.9% 33.5% 0.4% 1.2% 34.6% 
Cost  20.1% 8.1% 8.1% 17.6% 8.3% 10.4% 
Pearson Chi-square tests for column proportions with preference for inhaled insulin as dependent variable and 
product differentiation on performance of competing products as independent variables. Shaded regions depict 
statistically significant results at p < .001 for safety, efficacy, and convenience in both the comparisons; at p < 0.05 
for cost in inhaled vs. syringe/vial comparison. 
 
 
Multivariable Logistic Regression 
            In order to predict the preference for inhaled insulin, 2 multivariable logistic regressions 
were run using four summated-scale score variables each for performance comparisons of 
inhaled insulin vs. pen insulin, and inhaled insulin vs. syringe/vial insulin. The results obtained 
have been mentioned in Table XVI below. 
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Table XVI: Multivariable logistic regression results when patients’ preferences for inhaled 
insulin is the dependent variable 
 Inhaled vs. pen insulin Inhaled vs. syringe/vial insulin 
 Sig. OR 95% C.I. for OR Sig OR 95% C.I. for OR 
Clinical Efficacy .036   .6   
(1) Worse .033 0.41 (.181-.931) .316 .673 (.31-1.459) 
(2) Not differentiated 
(Ref) 
      
(3) Better .802 1.075 (.611-1.891) .645 .871 (.485-1.567) 
Safety .173   .019   
(1) Worse .695 1.21 (.466-3.142) .836 1.1 (.424-2.889) 
(2) Not differentiated 
(Ref) 
      
(3) Better .083 1.817 (.926-3.566) .017 2.356 (1.166-4.759) 
Convenience .001   .019   
(1) Worse .297 0.485 (.125-1.889) .673 1.487 (.236-9.387) 
(2) Not differentiated 
(Ref) 
      
(3) Better .029 2.873 (1.115-7.4) .01 4.032 (1.395-11.655) 
Cost .083   .006   
(1) Worse .073 .591 (.333-1.05) .004 .433 (.245-.766) 
(2) Not differentiated 
(Ref) 
      
(3) Better .028 .465 (.235-.92) .313 .715 (.373-1.372) 
 
 
            With the help of multivariable logistic regression, the strongest drivers of preference for 
inhaled insulin were observed for two comparisons: inhaled insulin versus pen insulin and 
inhaled insulin versus syringe/vial insulin. When inhaled insulin was compared to pen insulin, 
performance differentiation (based on summated-scale score variables for performance) on 
efficacy and convenience demonstrated a statistically significant relationship with the preference 
for inhaled insulin. When the products were compared for their performances on efficacy, the 
odds ratio demonstrated that the respondents for whom the inhaled insulin performed “worse” 
compared to those for whom inhaled insulin was “not differentiated” from pen insulin, were 
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significantly less likely to prefer inhaled insulin. Whereas in the case of convenience, the 
respondents who rated inhaled insulin to be “better than” in comparison to “not differentiated” 
from pen insulin, were 2.8 times more likely to prefer inhaled insulin.   
             Similarly, when inhaled insulin was compared to syringe/vial insulin, performance 
differentiation on safety, convenience, and cost demonstrated a statistically significant 
relationship with the preference for inhaled insulin. Product comparison on safety and 
convenience revealed that the patients, who rated inhaled insulin as “better than” in comparison 
to “not differentiated” with syringe/vial, were 2.3 and 4 times, respectively, more likely to prefer 
inhaled insulin. Patients, who rated the cost attribute of inhaled insulin to be “worse than” in 
comparison to “not differentiated” from syringe/vial, were significantly less likely to prefer 
inhaled insulin. 
 
Objective 2: To explore differences in the insulin users and insulin naïve (not taking insulin) 
diabetic patients in terms of value drivers for the new inhaled insulin product. 
 
            Apart from exploring the value drivers of inhaled insulin in Type 2 diabetic patients, the 
second objective of this study was to examine and compare these value drivers in insulin and 
non-insulin user sub-groups of the Type 2 diabetic sample. In order to meet with this objective, 
the two groups (insulin naïve and insulin-using diabetic patients) were explored for differences 
in their perceptions about importance of product attributes, product differentiation based on the 
performance of product attributes and their preferences for inhaled insulin.  
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Importance of product attributes – Group differences 
            The differences between two groups in terms of importance of attributes were explored 
based upon the Pearson chi-square statistics for column proportions and the independent sample 
t-tests for column means. Column proportions for importance attributes were examined at two 
levels, “Medium importance” (for those who marked the importance of an item less than 6 on a 
7-point Likert type scale) and “High importance” (for those who marked it more than or equal to 
6 on a 7-point Likert type scale). Based on Pearson chi-square tests, a higher percentage of 
patients in the insulin-naïve group compared to the insulin-using group placed high importance 
on the clinical efficacy, safety and convenience of an insulin product. As far as importance of 
cost of a product was concerned, both groups were similar. In terms of group means, independent 
sample t-tests revealed statistically significant difference among the 2 groups on safety and 
convenience. 
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Table XVII: Differences in the perceptions of insulin-naïve and insulin-using patients based 
on the importance that they place on product attributes 
Product attributes 
Insulin naïve Insulin users 
Importance 
ratings 
Percentage of 
patients in top 2 
boxes (6 & 7) 
Importance 
ratings 
Percentage of 
patients in top 2 
boxes (6 & 7) 
Control blood sugar levels to 
goal levels 
6.38(0.93) 236(92.5%) 6.38(0.86) 208(91.2%) 
Keeping your blood sugar 
levels stable* 
6.39(0.88) 235(92.2%) 6.28(0.95) 197(86.4%) 
Fasting blood sugar levels to 
goal levels 
5.94(0.99) 195(76.5%) 5.93(1.09) 171(75.0%) 
Post-prandial glucose levels to 
goal levels*# 
5.95(0.99) 190(74.5%) 5.64(1.21) 136(59.6%) 
Clinical Efficacy* 6.17(0.83) 196(76.9%) 6.06(0.88) 150(65.8%) 
Avoiding Symptoms of low 
blood sugar or hypoglycemia 
6.42(0.92) 234(91.8%) 6.28(1.09) 199(87.3%) 
Reducing the possible side 
effects of insulin medication, 
like allergic reactions*# 
6.21(1.00) 214(83.9%) 5.76(1.28) 153(67.1%) 
Minimizing weight gain from 
insulin therapy*# 
6.27(0.95) 216(84.7%) 6.04(1.19) 173(75.9%) 
Safety*# 6.30(0.82) 208(81.6%) 6.03(0.98) 156(68.4%) 
Flexibility in time required 
between insulin dose and 
eating*# 
5.88(1.06) 178(69.8%) 5.51(1.22) 123(53.9%) 
Minimizing the frequency of 
monitoring blood sugar with 
finger-stick test 
5.59(1.21) 153(60.0%) 5.54(1.23) 123(53.9%) 
Convenient for me to carry 
with me during the day*# 
5.86(1.19) 189(74.1%) 5.62(1.40) 141(61.8%) 
Making it easy to take insulin 5.52(1.35) 152(59.6%) 5.24(1.63) 119(52.2%) 
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in a public place# 
Reducing the pain or 
discomfort of taking insulin*# 
5.82(1.24) 171(67.1%) 5.32(1.52) 113(49.6%) 
Making it easy to accurately 
measure the correct dose of 
insulin*# 
6.32(0.98) 227(89.0%) 6.04(1.17) 175(76.8%) 
Convenience*# 5.83(0.89) 139(54.5%) 5.54(1.07) 97(42.5%) 
Selecting the best product I can 
afford 
5.94(1.28) 198(77.6%) 5.91(1.39) 172(75.4%) 
Selecting the products with the 
lowest out-of-pocket costs 
5.50(1.50) 148(58.0%) 5.56(1.57) 141(61.8%) 
Selecting a product that I can 
afford 
5.89(1.33) 188(73.7%) 5.67(1.59) 153(67.1%) 
Cost 5.78(1.26) 154(60.4%) 5.71(1.42) 141(61.8%) 
Comparisons based upon the Pearson chi-square* statistics for column proportions and the t-test# for column means 
showed significant difference in the importance of product attribute in two groups at p < 0.05 significance level. 
 
Performance of competing products on product attributes – Group differences  
            The percentage distribution of diabetic patients who defined inhaled insulin to be worse, 
undifferentiated, or better in comparison to pen insulin was explored in both insulin-user and 
insulin naïve sub-groups.  
            A similar trend was observed in both the sub-groups, with inhaled insulin performing 
better than pen and syringe/vial insulin in efficacy, safety, and convenience. The two subgroups 
were significantly different in terms of product differentiation on cost attribute, where a higher 
number (63.1% for inhaled vs. pen, and 60% for inhaled vs. syringe/vial) of patients in the 
insulin-naïve than in the insulin-user group (50.4% for inhaled vs. pen, and 51.8% for inhaled vs. 
syringe/vial) rated inhaled insulin to be worse than its competitors (both pen insulin and 
syringe/vial insulin). The two comparisons (inhaled insulin vs. pen and inhaled insulin vs. 
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syringe) had similar distributions, except for convenience. The majority of patients in both the 
sub-groups of the diabetic sample found inhaled insulin to be better than syringe/vial for 
convenience. 
 
Table XVIII: Cross tab results for product differentiation to explore differences among 
insulin naïve and insulin using patients.  
Product attributes Insulin naïve Insulin using Sig (2-sided) 
Efficacy - inhaled 
vs. pen  
Worse 44(17.3%) 47(20.6%) 
.455 Not differentiated 55(21.6%) 54(23.7%) 
  Better  156(61.2%) 127(55.7%) 
Safety – inhaled vs. 
pen 
Worse 36(14.1%) 37(16.2%) 
.501 Not differentiated 45(17.6%) 47(20.6%) 
Better  174(68.2%) 144(63.2%) 
Convenience – 
inhaled vs. pen  
Worse 30(11.8%) 26(11.4%) 
.412 Not differentiated 20(7.8%) 26(11.4%) 
Better  205(80.4%) 176(77.2%) 
Cost – inhaled vs. 
pen  
Worse 161(63.1%) 115(50.4%) 
.001 Not differentiated 57(22.4%) 50(21.9%) 
Better  37(14.5%) 63(27.6%) 
Efficacy - inhaled 
vs. syringe 
Worse 40(15.7%) 46(20.2%) 
.435 Not differentiated 54(21.2%) 45(19.7%) 
  Better  161(63.1%) 137(60.1%) 
Safety – inhaled vs. 
syringe 
Worse 31(12.2%) 35(15.4%) 
.157 Not differentiated 41(16.1%) 48(21.1%) 
Better  183(71.8%) 145(63.6%) 
Convenience – 
inhaled vs. syringe  
Worse 8(3.1%) 12(5.3%) 
.082 Not differentiated 17(6.7%) 26(11.4%) 
Better  230(90.2%) 190(83.3%) 
Cost – inhaled vs. 
syringe  
Worse 153(60.0%) 118(51.8%) 
.029 Not differentiated 59(23.1%) 49(21.5%) 
Better  43(16.9%) 61(26.8%) 
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Product attribute variables and preference for inhaled insulin 
            With the help of univariable logistic regression, the relationship between importance 
variables for product attributes and preference for inhaled insulin was examined. Table XIX 
shows the result of univariable logistic regression for the insulin-user sub-group and insulin-
naïve sub-group of diabetic patients, respectively.   
            In insulin users, importance placed on safety (Wald = 4.588, p = 0.032), and convenience 
(Wald = 7.785, p = 0.005) significantly predicted the preference for inhaled insulin. Based on 
odds ratio, the patients were 2.28 and 2.46 times more likely to prefer inhaled insulin if they 
marked safety and convenience of a product to be of high importance in comparison to low 
importance. 
 
Table XIX. Results of univariate logistic regression models between perceived importance 
of product attribute measures and preference for inhaled insulin    
Product attributes 
Insulin users Insulin naïve 
OR 95% C.I. for OR OR 95% C.I. for OR 
Clinical Efficacy 1.092 (0.56-2.1) 1.04 (0.58-1.86) 
Safety 2.284 (1.07-4.86) 1.642 (0.86-3.13) 
Convenience 2.46 (1.3-4.63) 1.06 (0.65-1.74) 
Cost 1.52 (0.78-2.95) 1.048 (0.63-1.73) 
Shaded regions depict statistically significant differences at p < 0.05 level.      
 
            When univariable logistic regression was conducted for insulin naïve patients, none of 
the product attributes significantly predicted their preference for inhaled insulin.  
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            The results of chi-square tests between performance comparisons and preference for 
inhaled insulin are described in Table XX. Among insulin users, when inhaled insulin was 
compared with pen insulin, a statistically significant relationship was found between the 
preference for inhaled insulin and performance of efficacy and safety; whereas, when inhaled 
insulin was compared against syringe/vial insulin, a statistically significant relationship was 
found between the preference for inhaled insulin and performance of safety. When similar tests 
were run among insulin-naïve patients, the performances of comparative products on all the four 
product attributes had a statistically significant relationship with the preference for inhaled 
insulin. Considering the results from Table XIX, it seems like for the insulin-naïve subgroup of 
diabetic patients, the performance of products is more important than achieving specific goals in 
their product-selection criteria. 
 
Table XX. Categorical summated-scale score variables for performance of insulin products 
vs. preference for inhaled insulin among insulin-user and insulin-naïve diabetic patients 
Product attributes 
Inhaled insulin vs. pen insulin Inhaled vs. syringe/vial insulin 
Worse Not differentiate Better Worse Not differentiate Better 
Insulin users 
Efficacy  1.8% 5.7% 15.4% 3.5% 4.4% 14.9% 
Safety  1.3% 3.5% 18.0% 1.3% 3.1% 18.4% 
Convenience  0.9% 1.8% 20.2% 0.4% 1.3% 21.1% 
Cost  12.7% 4.8% 5.3% 10.1% 5.3% 7.5% 
Insulin naïve  
Efficacy  3.9% 9.0% 35.3% 4.7% 7.8% 35.7% 
Safety  3.5% 6.3% 38.4% 3.5% 5.1% 39.6% 
Convenience  0.8% 2.0% 45.5% 0.4% 1.2% 46.7% 
Cost  26.7% 11.0% 10.6% 24.3% 11.0% 12.9% 
Pearson Chi-square tests for column proportions with preference for inhaled insulin as dependent variable and 
product differentiation on performance of competing products as independent variables. Shaded columns represent 
statistically significant differences between the product differentiation and preference of inhaled insulin at p < 0.05 
(light shade), and p < 0.001 (dark shade).   
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Multivariable logistic regression 
            The results obtained from the multivariable logistic regression for the insulin-user sub-
group of diabetic patients can be seen in Table XXI. In this subgroup of patients, we found that 
none of the summated-scale score variables for performance of competing products significantly 
predicted the preference of inhaled insulin.  
 
Table XXI. Multivariable logistic regression results for insulin-user diabetic patients when 
preference to use inhaled insulin is the dependent variable 
 Inhaled vs. pen insulin Inhaled vs. syringe/vial insulin 
 Sig. OR 95% C.I. for OR Sig OR 95% C.I. for OR 
Efficacy .207   .5   
(1) Worse .106 .317 (.079-1.275) .681 .774 (.228-2.629) 
(2) Not differentiated 
(Ref) 
      
(3) Better .93 .959 (.377-2.441) .255 .556 (.203-1.525) 
Safety .139   .071   
(1) Worse .873 .875 (.169-4.532) .618 .652 (.121-3.505) 
(2) Not differentiated 
(Ref) 
      
(3) Better .114 2.398 (.811-7.091) .092 2.71 (.85-8.636) 
Convenience .558   .416   
(1) Worse .842 .812 (.105-6.298) .655 1.852 (.125-25.517) 
(2) Not differentiated 
(Ref) 
      
(3) Better .477 1.677 (.403-6.972) .22 2.721 (.55-13.474) 
Cost .07   .441   
(1) Worse .823 .896 (.344-2.338) .185 .528 (.205-1.359) 
(2) Not differentiated 
(Ref) 
      
(3) Better .076 .353 (.111-1.116) .419 .651 (.23-1.843) 
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             Further, the same model was run in the insulin-naïve sub-group of diabetic patients 
(Table XXII). Here, performance of convenience, cost for inhaled vs. pen and cost performance 
of inhaled vs. syringe were found to have statistically significant relationships with the 
preference for inhaled insulin. When inhaled insulin was compared to pen insulin, the 
respondents who rated inhaled insulin on convenience “better than” in comparison to those who 
rated it ‘not differentiated’ from pen insulin were 4.1 times more likely to prefer inhaled insulin. 
For the cost performance in both product comparisons, the respondents who rated inhaled insulin 
to be “worse” in comparison to “not differentiated” from pen insulin were significantly less 
likely to prefer inhaled insulin.  
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Table XXII. Multivariable logistic regression results for insulin-naïve diabetic patients 
when preference to use inhaled insulin is the dependent variable 
 Inhaled vs. pen insulin Inhaled vs. syringe/vial insulin 
 Sig. OR 95% C.I. for OR Sig OR 95% C.I. for OR 
Efficacy .215   .383   
(1) Worse .138 .435 (.145-1.307) .385 .629 (.221-1.791) 
(2) Not differentiated 
(Ref) 
      
(3) Better .937 1.03 (.482-2.207) .652 1.189 (.561-2.52) 
Safety .569   .203   
(1) Worse .586 1.436 (.39-5.281) .556 1.472 (.406-5.334) 
(2) Not differentiated 
(Ref) 
      
(3) Better .288 1.665 (.65-4.266) .09 2.336 (.876-6.234) 
Convenience .001   .081   
(4) Worse .244 .326 (.049-2.152) .958 .931 (.065-13.399) 
(1) Not differentiated 
(Ref) 
      
(2) Better .035 4.156 (1.109-15.58) .063 4.134 (.926-18.443) 
Cost .011   <.001   
(1) Worse .034 .425 (.193-.937) .018 .393 (.181-.853) 
(2) Not differentiated 
(Ref) 
      
(3) Better .657 1.263 (.452-3.53) .258 1.778 (.655-4.825) 
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CHAPTER V – DISCUSSION 
 
            This study presents a unique methodology for not only exploring the potential value 
drivers for a new pharmaceutical product, but also for developing strategic insights to aid 
pharmaceutical companies in making critical decisions regarding product promotion. In 
pharmaceutical marketing, the product preference and decision analytic approaches are 
commonly used to compare new drug products with their competitors. However, using the 
SVDM approach not only identifies key value drivers, but also provides strategic insights into 
the value drivers that can be used to develop marketing strategies. 
            Prior research suggests that convenience issues of insulin treatment like flexibility of 
treatment, social comfort, ease of use and reduced pain from injections are important issues for 
insulin-user diabetic patients (Testa & Simonson 2007; Kadiri et al., 1998). However, research in 
the area of preference for insulin products has not focused on all the attributes of a product and 
for the most part, differences in the products were based on the convenience and ease of use of 
the insulin products (Testa & Simonson, 2007; Pinto et al., 2009; Rosenstock et al., 2004).  
Therefore, the main objective of this study was to examine the role of product attributes in the 
decision to purchase inhaled insulin. The product attributes were examined from a marketing 
standpoint as it will be critical for the manufacturer of new inhaled insulin to measure patients’ 
perceptions about the product and identify ways to effectively differentiate the new product from 
traditionally available insulin products. 
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Importance of product attributes measures 
            Results indicated that diabetes patients’ considered clinical efficacy and safety of the 
insulin products to be very important. Insulin users and insulin-naïve patients were significantly 
different from each other in terms of the amount of importance they placed on clinical efficacy, 
safety, and convenience. A higher percentage of insulin naïve patients placed high importance on 
clinical efficacy, safety and convenience than insulin-user patients (76.9% vs. 65.8% for 
efficacy, 81.6% vs. 68.4% for safety, and 54.5% vs. 45.2% for convenience, respectively) 
(Figure IV). As far as importance of cost of a product was concerned, both the groups were 
similar. 
 
Figure IV: Difference in the perception of insulin naïve and insulin using patients based on 
the importance that they place on product attributes 
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             In type 2 diabetic patients, stated importance for safety (Wald = 10.717, P = 0.001), and 
convenience (Wald = 6.49, P = 0.011) significantly predicted the preference for inhaled insulin. 
Interestingly, in the insulin-user subgroup, safety and convenience significantly predicted the 
preference for inhaled insulin; in contrast, in the insulin-naïve subgroup, stated importance of 
product attributes did not predict the preference for inhaled insulin. This indicates that in insulin-
naïve patients, preference for inhaled insulin is primarily driven by the performance of products 
rather than the importance of achieving specific treatment goals. This piece of information could 
be used by the manufacturer of a new inhaled insulin product in targeting insulin-naïve patients 
and promoting better performance of a new product (in comparison to its competitors) rather 
than teaching them about the importance of achieving various insulin treatment goals via DTCA 
(Direct To Consumer Advertisements). On the other hand, if our target is the insulin-user 
subgroup, better safety and convenience of the new product should be promoted.  
 
Performance on product attributes 
            When inhaled insulin was compared to pen insulin, convenience was found to be the 
major value driver for the preference of inhaled insulin. 78.8% of the patients perceived inhaled 
insulin to be better than the pen for convenience, and 33.5% of patients who preferred inhaled 
insulin were from this category (Figure V). Similarly, when comparing inhaled insulin with 
syringe/vials for convenience, 86.9% of the patients perceived inhaled insulin’s performance to 
be better than syringe/vial, and 34.6% of patients who preferred inhaled insulin were from this 
category (Figure VI). Additionally, the results indicated that patients are going to prefer inhaled 
insulin only if they perceive it to be better (in comparison to the “not differentiated” and “worse” 
categories) in convenience than its competitors. Therefore, the new inhaled insulin should be 
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promoted as a more convenient insulin product in comparison to pen insulin. Specifically, the 
convenience items with high stated importance, like “making it easy to accurately measure the 
correct dose of insulin”, “convenient for me to carry with me during the day,” and “flexibility in 
time required between insulin doses and eating” should be focused on. As far as safety and 
efficacy attributes were concerned, the majority of patients who preferred inhaled insulin came 
from the group of patients that perceived inhaled insulin to perform better in these attributes than 
its competitors.  In contrast, perceived performance of cost provided slightly different results. 
We observed that patients who preferred inhaled insulin over other products often rated inhaled 
insulin as worse on cost. This indicates that for some patients, convenience and other product 
performance attributes are more important than cost.   
 
Figure V: Comparing product differentiation among inhaled insulin and pen insulin with 
preference for inhaled insulin 
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Figure VI: Comparing product differentiation among inhaled insulin and syringe/vial 
insulin with preference for inhaled insulin 
 
             
            Multivariable logistic regression was used to identify the strongest drivers of preference 
of inhaled insulin. Performance of clinical efficacy and convenience were the strongest 
predictors of preference for inhaled insulin when inhaled insulin was compared against pen 
insulin. However, when inhaled insulin was compared with syringe/vial insulin, performance of 
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inhaled insulin when inhaled insulin was compared to syringe/vial insulin. Interestingly, among 
insulin users none of the product performance comparisons significantly predicted preference for 
inhaled insulin. This effect may be attributable to the following reasons: (1) the decision making 
of insulin users may depend to a certain extent on the performance of all the product attributes, 
or (2) the percentage of insulin users that preferred inhaled insulin was very low, which may 
have resulted in diminished effects. Therefore, from product promotion standpoint, it may prove 
valuable to decide whether it is cost effective to target insulin users at all or to focus only on 
insulin-naïve patients (48.2% of insulin-naïve patients as compared to 22.8% of insulin-user 
preferred inhaled insulin). 
  
Product Preference  
            When the patients were asked to assume no difference in the cost of the products, inhaled 
insulin was the most preferred product (57.5%). However, introduction of the cost for inhaled 
insulin significantly reduced product preference. We found that inhaled insulin and insulin pen 
were equally preferred products (36.9% and 36.3%, respectively). Furthermore, the comparison 
of two subgroups indicated that a higher percentage of insulin-naïve patients, in comparison to 
insulin-user, preferred inhaled insulin. On exploring the preferences at these two levels, with 
introduction of cost, we observed that some insulin-naïve patients switched to the insulin pen, 
while insulin users switched to insulin syringe/vials.   
 
 
 
 
72 
 
Figure VII: Product preferences of Type 2 diabetic patients with no difference in the cost of 
the products 
 
 
Figure VIII: Product preferences of Type 2 diabetic patients on considering out-of-pocket 
monthly cost of the products 
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Strategy development for the promotion of new inhaled insulin product 
            Due to the complex nature of the US health care system, where the decision to adopt a 
new drug product depends on a wide gamut of factors, it becomes critical for the manufacturer to 
develop effective strategies for promoting a new product. The results obtained from this study 
could be used to understand the dynamics of the diabetes market and will also help the 
manufacturers identify the group of diabetic patients that would be more likely to prefer the new 
product. 
             The stated and derived importance of product attributes allow us to infer that out of four 
product attributes, clinical efficacy and safety were very important for diabetic patients; and 
based on the information provided to them (along with their prior knowledge of diabetes), the 
majority of them perceived inhaled insulin to perform better than its competitor. Hence, it would 
be critical to differentiate the new drug product on clinical efficacy and safety from its 
competitors while promoting inhaled insulin. Promoting better efficacy and safety profiles of 
inhaled insulin would be more beneficial because traditionally available insulin products, i.e., the 
insulin syringe and insulin pen, are similar in terms of efficacy and safety. Overall, the 
convenience attribute was less important than clinical efficacy and safety, but the new inhaled 
insulin was perceived to be best among its competitors (in terms of convenience). Therefore, it 
would be important for the manufacturer to promote the convenience of the new inhaled insulin 
product. The payoff (in terms of preference for inhaled insulin) was found to be approximately 
50% in the case of each product attribute, which could be due to an overlap of product 
differentiation (e.g., inhaled insulin might be perceived to perform better in one attribute, but not 
in another attribute, which might be more important to this particular patient) or some unknown 
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concerns (or unmeasured factors in this study) from the patients’ perspectives in adopting a new 
drug product.  
            Patient co-pays or out-of-pocket costs have been significant barriers when it comes to 
adoption of new drug products. Even though, various studies confirmed greater satisfaction with 
the use of Exubera (inhaled insulin that was developed and marketed by Pfizer and recalled in 
2007), with the majority of patients preferring it over injectable insulin, a recent study found that 
the amount that diabetic patients were willing to pay for Exubera was approximately equal to 
what they were paying for their traditional insulin therapy (Pinto et al., 2009; Rosenstock et al., 
2004; Cappelleri, Cefalu, Rosenstock, Kourides, & Gerber, 2002; Freemantle et al., 2005). 
Although the inhaled insulin product examined in these studies was different, cost was still found 
to be a major barrier in the adoption of new inhaled insulin. The results from our study confirm 
that cost indeed plays a major role, even if the new product is perceived to be better than its 
competitors in not only convenience but also safety and efficacy profiles. However, we observed 
a group of patients who classified cost of inhaled insulin to be worse than its competitors but still 
preferred inhaled insulin over injectable insulin. A possible explanation for this could be that: (1) 
this group of patients is cost insensitive, and they are willing to pay higher for a product with 
better overall perceived value (which could be from better convenience or safety of inhaled 
insulin), or (2) this group of patients includes a higher number of insulin-naïve patients (70.1% 
in inhaled vs. pen and 72.94% in inhaled vs. syringe/vial comparisons).  
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Figure IX: Product differentiation for cost-insensitive patients among inhaled insulin and 
syringe/vial insulin with preference for inhaled insulin 
 
 
Figure X: Product differentiation for cost-insensitive patients among inhaled insulin and 
syringe/vial insulin with preference for inhaled insulin 
 
  
             Therefore, it will be critical for the manufacturer of new inhaled insulin to develop some 
strategies to minimize out-of-pocket cost as a barrier, either in terms of rebates and placing the 
product on the 2nd or 3rd tier in health-care plans, or providing diabetic patients who are new to 
insulin therapy with coupons of new inhaled insulin.  
         
0%
20%
40%
60%
80%
100%
Efficacy Safety Covnenience
%
 o
f P
at
ie
nt
s
Cost insensitive group in inhaled vs. pen comparison
Worst
Undifferentiated
Better
0%
20%
40%
60%
80%
100%
Efficacy Safety Covnenience
%
 o
f p
at
ie
nt
s
Cost insensitive group in inhaled vs. syringe comparison
Worst
Undifferentiated
Better
76 
 
Limitations of the study 
             Since a higher percentage of diabetic patients use pen insulin in Europe and the UK in 
comparison to the US, expanding this study outside of the US may provide different information 
on value drivers for inhaled insulin. Also, the methodology (SVDM) used for this study needs 
further validation in different settings (e.g., study sample and products compared). Derivation of 
summated-scale score variables for performance differentiation may have resulted in the loss of 
information, specifically the accuracy and extent to which a product performed (“Worse” or 
“Better”) on an attribute in relation to its competitor. Furthermore, as with any cross-sectional 
study, this study did not provide evidence for causal relationships between the variables. 
            The use of an online panel of diabetic patients may have resulted in selection bias, since 
internet users might be more educated and knowledgeable about diabetes in general. In addition, 
the way that information about the products was revealed to the patients in the online survey 
might not replicate the natural learning process of the patients, which may have influenced the 
results in the process. 
            A major limitation that was identified for this study is that almost all of the insulin-user 
patients had prior experience with Exubera. Future research is required to examine insulin-user 
diabetic patients with no prior experience with Exubera. Also, since our study sample included 
only Type 2 diabetic patients, the results could not be generalized to Type 1 diabetic patients. 
Future research should explore value drivers of inhaled insulin in Type 1 diabetic patients. 
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Thank you for being a part of this important research pertaining to diabetes. You will be asked to 
read a short story and then respond to a group of questions about diabetes medication. Your 
thoughtful responses are very important to us. Several others have been invited to share their 
thoughts with us on this topic as well.  
 
Although the information collected as a result of this project may be shared in presentations and 
publications, your individual responses are confidential and will not be shared with anyone outside 
the university research team. As there is no right or wrong answer to any item, please respond to 
each item according to how you feel about your diabetes at this point in time. I appreciate your 
taking the time to complete the survey.  We anticipate the survey will take between 10-15 minutes 
to complete. 
 
Your participation in this study is voluntary. Your choosing not to participate will not affect your 
relationship with The University of Mississippi. This study has been reviewed by The University of 
Mississippi’s Institutional Review Board (IRB). The IRB has determined that this study fulfills the 
human research subject protections obligations required by state and federal law and University 
policies. If you have any questions, concerns, or reports regarding your rights as a participant of 
this research, please contact the IRB at 662-915-7482. 
 
Clicking >> (next) means that you are consenting to participate in this research project. 
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Section I - Diabetes screener 
 
1. Which of the following has your doctor diagnosed you with? Check all that apply.   
ROTATE CHOICES EXCEPT (8) 
 High blood pressure  
 Diabetes or high blood sugar (DISQUALIFY IF DIABETES OR HIGH BLOOD SUGAR IS NOT 
SELECTED) 
 Obesity/overweight  
 High cholesterol/hyperlipidemia  
 Depression  
 Asthma  
 COPD (chronic obstructive pulmonary disorder)  
 None of the above 
  
 
2. How is your current diagnosis of diabetes classified? 
 Type 2 (DISQUALIFY IF TYPQ 2 NOT SELECTED) 
 Type 1  
 Other  
 Don’t know  
 
 
3. For how many years have you had Type 2 diabetes?___ years 
 
 
 
4. What do you currently take for controlling your high blood sugar levels? Check all that apply. 
                                                                                    
 Diet and exercise (DISQUALIFY IF B OR C NOT SELECTED) 
 Take medications by mouth (GO TO Q5) 
 Insulin injections/shots (GO TO Q6)  
 Insulin pump (DISQUALIFY IF B OR C NOT SELECTED) 
 Byetta or Victoza (DISQUALIFY IF B OR C NOT SELECTED) 
 Other (specify) ___________ (DISQUALIFY IF B OR C NOT SELECTED) 
 
5. Which of the following types of oral anti-diabetic medication(s) are currently taking? NOTE that the 
combination drug products are listed under both categories; therefore, if you are using a combination 
product, PLEASE check both categories. (Check ALL that apply) 
 Sulphonylureas (Dymelor or generic Acetohexamide, Diabinese or generic Chlorpropamide,Tolinase 
or generic Tolazamide, Orinase or generic Tolbutamide, Amaryl or generic Glimepiride, Glucotrol or 
generic Glipizide, DiaBeta or generic Glyburide, Duetact, Avandaryl, Metaglip, Glucovance)  
 Meglitinides (Starlix or generic Nateglinide, Prandin or generic Repaglinide, Prandimet) 
 Biguanides (Glucophage or generic Metformin, Metaglip, Avandamet, ActoPlusMet, Prandimet, 
Janumet, Glucovance) 
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 Thiazolidinediones (Actos or generic Pioglitazone, Avandia or generic Rosiglitazone, Duetact, 
Avandaryl, Avandamet, ActoPlusMet) 
 Alpha-glucosidease Inhibitors (Precose or generic Acarbose, Glyset or generic Miglitol) 
 DPP-4 Inhibitors (Januvia or generic Sitagliptin, Janumet) 
(DISQUALIFY IF Q5 COUNT IS LESS THAN 2 AND IF DID NOT CHECK 3 IN Q4, OTHERWISE GO 
TO Q15)  
 
 
Section II – Qualified diabetic patients 
 
6. How do you inject insulin?  
 Use a pen device to inject insulin (GO TO 7) 
 Use an insulin needle/syringe (GO TO 8)  
 Use a pen sometimes and insulin needle/syringe other times  
 Other (please specify) _______ (GO TO 9) 
 
 
DISPLAY Q7 IF CHECKED 1 IN Q6 
7. Have you ever used an insulin needle/syringe as a method for taking insulin  
 Yes 
 No  
 
 
DISPLAY Q8 IF CHECKED 2 IN Q6 
8. Have you ever used pen devices as a method for taking insulin  
 Yes  
 No  
 
 
DISPLAY Q9 IF CHECKED 3 IN Q4 
9. Have you ever used Exubera for taking insulin? 
 Yes 
 No 
 
 
DISPLAY Q10 IF CHECKED 3 IN Q4 
10. How long have you been taking insulin? ____ years 
 
DISPLAY Q10 IF CHECKED 3 IN Q4 
11. How many times during the day do you take the following types of insulin? (PLEASE enter ‘0’ if you do 
not take a specific type) 
 Rapid/Short acting insulin (NovoLog OR Humalog OR Apidra OR Humulin R OR Novolin R): _____  
 Intermediate acting insulin (Humulin N OR Novolin N OR U-500): _____  
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 Long acting insulin (Lantus OR Levemir): _____  
 Premixed insulin (Humulin Mix 50/50 OR Humulin 70/30 OR Novolin 70/30 OR Humalog Mix 75/25 
OR NovoLog Mix 70/30): ______  
 
 
DISPLAY Q10 IF CHECKED 1 OR 3 IN Q6 
12. How satisfied are you with the insulin needle/syringe that you are currently using to inject insulin? 
 Very dissatisfied (GO TO Q15) 
 Somewhat dissatisfied (GO TO Q15) 
 Not sure 
 Somewhat satisfied 
 Very satisfied 
 
 
DISPLAY Q10 IF CHECKED 2 OR 3 IN Q6 
13. How satisfied are you with the insulin pen that you are currently using to inject insulin? 
 Very dissatisfied (GO TO Q15) 
 Dissatisfied (GO TO Q15) 
 Neutral 
 Satisfied 
 Very satisfied 
 
DISPLAY Q10 IF CHECKED 3 IN Q4 
14. Please rate the amount of pain you experience from injections on a scale of 1 to 7,  where 1 means ‘No 
pain’ and 7 means ‘Worst possible pain’ when you take: 
 
 1 – “No 
Pain” 
2 3 4 5 6 7 – 
“Worst 
Possible 
Pain” 
Not 
Applicable 
Insulin 
needle/syringe 
o  o  o  o  o  o  o  o  
Insulin pen o  o  o  o  o  o  o  o  
 
 
DISPLAY IF Q15 IF CHECKED 1 OR 2 IN Q12 OR Q13  
15. You said you were dissatisfied with your current method for injecting insulin. What are the probable 
reasons for your dissatisfaction? (Check ALL that apply) 
 Hypoglycemia 
 Weight gain 
 Too expensive 
 Need to monitor blood sugar too often with finger-stick test  
 Not effective in controlling my blood sugar levels 
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 Need to take too many doses/day 
 Inconvenient 
 Other (specify) ________ 
 
 
16. Do you currently have any type of insurance that pays all or part of your: 
 Yes No Don’t know 
Diabetes medication (oral anti-diabetic drugs or 
insulin) 
ο  ο  ο  
Insulin devices (needles/syringes) ο  ο  ο  
 
 
17. How well do you understand the importance of the following: 
 
 Not at all 
important 
Very 
unimportant 
Somewhat 
unimportant 
Neither 
important 
nor 
unimportant 
Somewhat 
important 
Very 
important 
Extremely 
Important 
HbA1c test (lab value for 
overall sugar control) and 
its meaning for a person 
with diabetes     
ο  ο  ο  ο  ο  ο  ο  
Achieving the required 
fasting (pre-meal) blood 
glucose levels 
ο  ο  ο  ο  ο  ο  ο  
Achieving the required 
post prandial (after meal) 
blood glucose levels 
ο  ο  ο  ο  ο  ο  ο  
 
 
18. What was the result of your last HbA1c test (lab value for overall sugar control)? 
 < 7% 
 7 - 7.9% 
 8 – 8.9% 
 9 - 9.9% 
 > 10% 
 Don’t know (GO TO Q20) 
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19. Based on the results of your last HbA1c test, your diabetes is in  
 Excellent control 
 Good control 
 Fair control 
 Poor control 
 Not sure 
 
20. Indicate the value that you would consider satisfactory for your HbA1c? _____% 
 
DISPLAY Q21 IF CHECKED 3 IN Q4 
21. While selecting an insulin product for managing diabetes, how important is it to achieve each of the 
following treatment goals? Please rate the important of each using the scale below: 
(ROTATE ITEMS) 
 
 
 Not at all 
important 
Very 
important 
Somewhat 
important 
Neither 
important 
nor 
unimportant 
Somewhat 
important 
Very 
important 
Extremely 
important 
Fasting (morning before breakfast) 
blood sugar (glucose) levels to goal 
levels 
ο  ο  ο  ο  ο  ο  ο  
Making it easy to take insulin in a 
public place (where people might 
see you) 
ο  ο  ο  ο  ο  ο  ο  
Convenient for me to carry with me 
during the day 
ο  ο  ο  ο  ο  ο  ο  
Post prandial (after meal) glucose 
levels to goal levels 
ο  ο  ο  ο  ο  ο  ο  
Control blood sugar (glucose) 
levels to goal levels 
ο  ο  ο  ο  ο  ο  ο  
Flexibility in time required between 
insulin doses and eating 
ο  ο  ο  ο  ο  ο  ο  
Selecting the best product I can 
afford 
ο  ο  ο  ο  ο  ο  ο  
Minimizing weight gain from 
insulin therapy 
ο  ο  ο  ο  ο  ο  ο  
Minimizing the frequency of 
monitoring blood sugar (glucose) 
with finger-stick test 
ο  ο  ο  ο  ο  ο  ο  
Making it easy to accurately 
measure the correct dose of insulin 
dose 
ο  ο  ο  ο  ο  ο  ο  
Avoiding symptoms of low blood 
sugar or hypoglycemia (such as 
sweating, trembling, dizziness, 
blurred vision and fast heart beat) 
ο  ο  ο  ο  ο  ο  ο  
Reducing the possible side effects ο  ο  ο  ο  ο  ο  ο  
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of insulin medication, like allergic 
reactions and reactions at the 
injection site which may cause 
redness, swelling and itching 
  
 
DISPLAY Q22 IF CHECKED 2 AND 3 IN Q4 
22. Assume you needed to use insulin to control your diabetes. When selecting an insulin product for managing 
diabetes, how important is it to achieve each of the following treatment goals? Please rate the importance of 
each using the scale below: 
(ROTATE ITEMS) 
 
 
 Not at all 
important 
Very 
important 
Somewhat 
important 
Neither 
important 
nor 
unimportant 
Somewhat 
important 
Very 
important 
Extremely 
important 
Fasting (morning before breakfast) 
blood sugar (glucose) levels to goal 
levels 
ο  ο  ο  ο  ο  ο  ο  
Making it easy to take insulin in a 
public place (where people might 
see you) 
ο  ο  ο  ο  ο  ο  ο  
Convenient for me to carry with me 
during the day 
ο  ο  ο  ο  ο  ο  ο  
Post prandial (after meal) glucose 
levels to goal levels 
ο  ο  ο  ο  ο  ο  ο  
Control blood sugar (glucose) 
levels to goal levels 
ο  ο  ο  ο  ο  ο  ο  
Flexibility in time required between 
insulin doses and eating 
ο  ο  ο  ο  ο  ο  ο  
Selecting the best product I can 
afford 
ο  ο  ο  ο  ο  ο  ο  
Minimizing weight gain from 
insulin therapy 
ο  ο  ο  ο  ο  ο  ο  
Minimizing the frequency of 
monitoring blood sugar (glucose) 
with finger-stick test 
ο  ο  ο  ο  ο  ο  ο  
Making it easy to accurately 
measure the correct dose of insulin 
dose 
ο  ο  ο  ο  ο  ο  ο  
Avoiding symptoms of low blood 
sugar or hypoglycemia (such as 
sweating, trembling, dizziness, 
blurred vision and fast heart beat) 
ο  ο  ο  ο  ο  ο  ο  
Reducing the possible side effects 
of insulin medication, like allergic 
reactions and reactions at the 
injection site which may cause 
redness, swelling and itching 
ο  ο  ο  ο  ο  ο  ο  
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(SHOW PRODUCT PROFILES) 
 
23. Earlier you rated how important the treatment goals were.  Now considering the product profiles you just 
read, please rate each product in terms of how well it may meet the treatment goals listed in the table below 
using a 7-point scale where: “1” = “Product performance is worst on this treatment goal” and “7” = 
“Product performance is best on this treatment goal.”  
If you are not sure how to rate a product on a treatment goal, please rate it as “0” to indicate that you do not 
have sufficient information. If you need to re-read the profile please scroll up and come back to answer the 
questions: 
(ROTATE ITEMS) 
Control blood sugar (glucose) levels to goal levels 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
 
 
Avoiding symptoms of low blood sugar or hypoglycemia (such as sweating, trembling, dizziness, 
blurred vision and fast heart beat) 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
 
Flexibility in time required between insulin doses and eating 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin            
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needle/syringe 
Insulin Pen            
Inhaled insulin            
 
Selecting a product that I can afford 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Minimizing the frequency of monitoring blood sugar (glucose) with finger-stick test 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Reducing the possible side effects of insulin medication, like allergic reactions and reactions at the 
injection site which may cause redness, swelling and itching 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
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Inhaled insulin            
 
Keeping your blood sugar levels stable (avoiding high and low blood sugar levels) 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Making it easy to accurately measure the correct dose of insulin dose 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Fasting (before breakfast) blood sugar (glucose) levels to goal levels 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
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Minimizing weight gain from insulin therapy 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Convenient for me to carry with me on a regular day 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Selecting the products with lower out-of-pocket cost 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
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Post-prandial (after meal) glucose levels to goal levels 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Making it easy to take insulin in a public place (where people might see you) 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
Reducing the pain or discomfort of taking insulin 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
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Selecting the best product I can afford 
 
 1 – “Product 
performance 
is WORST 
on this item” 
2 3 4 5 6 7 – “Product 
performance 
is BEST on 
this item” 
0 – “Do not 
have 
sufficient 
information” 
Insulin 
needle/syringe 
           
Insulin Pen            
Inhaled insulin            
 
24. Based on the information provided to you about 3 products, and if there was no difference in the cost of the 
products, which one of the following would you prefer? 
 Insulin needle/syringe 
 Insulin pen 
 Inhaled insulin 
 No preference, will take whatever the doctor prescribes 
25. Now consider the out-of-pocket monthly cost of taking insulin in the product information and your personal 
insurance coverage, which one of the following would you prefer? 
 Insulin needle/syringe 
 Insulin pen 
 Inhaled insulin 
 No preference, will take whatever the doctor prescribes 
 
26. Now assume that the next time you visit your doctor, your doctor asks you to start taking inhaled insulin to 
better control your blood sugar levels. He writes you a prescription for inhaled insulin considering your 
doctor’s recommendation and the information you just read for inhaled insulin, how likely would you be to 
be fell the prescription and begin using inhaled insulin? 
Very unlikely Unlikely Undecided Likely Very likely 
ο  ο  ο  ο  ο  
 
27. Assume that you read in a magazine or saw a promotional advertisement for inhaled insulin, if you needed 
to take short acting insulin, how likely would you be to ask your doctor about using the inhaled insulin? 
Very unlikely Unlikely Undecided Likely Very likely 
ο  ο  ο  ο  ο  
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28. In general, would you say your health is: (Check only one) 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
 
29. Which of the following best describes the highest grade or level of schooling you have completed or the 
highest degree you have earned? Check only one 
 
 Some grade school 
 Some high school 
 High school diploma 
 Some college 
 Associate’s degree 
 Bachelors degree 
 Master’s degree 
 Doctoral degree 
 Do not wish to answer 
 Other (please specify)_________ 
 
30. What was your approximate total annual household income before taxes last year? Check only one. 
 
 Under $5,000 
 $5000 to $9,999 
 $10,000 to $14,999 
 $15,000 to $24,999 
 $25,000 to $34,999 
 $35,000 to $49,999 
 $50,000 to $74,999 
 $75,000 to $99,999 
 $100,000 and above 
 Do not wish to answer 
 
31. Which of the following describes you? 
 
 I have never smoked (non-smoker) 
 I am a regular smoker 
 I am an occasional smoker 
 I used to smoke, but I do not smoke now (Ex-smoker)  
 
 
32. Gender:      
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 Male 
 Female 
 
33. Please fill in the following categories: 
Age (in year): ______  
Current Height (in feet, inches): ______  
Current Weight (in lbs, pounds): ______  
 
34. Ethnicity: 
 African-American/Black 
 American Indian/Alaska native 
 Asian/Asian Indian 
 Caucasian/white 
 Hispanic/Chicano/Latino 
 Native Hawaiian/ Pacific Islander 
 Other (please specify)_______ 
 
 
Thank you note (for disqualified respondents) 
Thank you for your willingness to participate in our survey. The survey is only relevant for Type 2 diabetic patients 
who are currently taking insulin or more than one oral anti-diabetic medication.  
 
Thank you note (after completion) 
This concludes your participation in the study. Thank you for your time! 
 
Click Here to Exit 
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Please take a few minutes to go through the information carefully and then answer the questions that follow. 
Insulin is a hormone that your body produces to help convert the food you eat into energy. For individuals that have 
been diagnosed with diabetes (high blood sugar levels), the body doesn't make enough insulin, or it can't effectively 
use the insulin it produces.  In these cases, the doctor may prescribe insulin therapy. Insulin therapy includes 
subcutaneous injections of insulin, which are often required to be taken multiples times a day.  The required dose of 
insulin depends on how your blood sugar levels are controlled and your doctors’ recommendation.   
As you may already be aware, there are several ways in which you can take insulin like using syringes/needles to 
take a shot of insulin from a vial and insulin pens.  Currently, there is a new form of rapid-acting insulin that is 
under development. This insulin does not need to be injected as the current insulin, rather it is inhaled.  The 
following information describes the different forms of rapid-acting insulin – vials/syringes, pens and inhaled.  Please 
read this information carefully and then answer the questions that follow. 
 
INSULIN THERAPY USING NEEDLES/VIALS – tried and true 
Insulin is available in a vial and the patient takes the required dose 
using a syringe.  A shot or injection is usually taken in the stomach, 
thighs or hands. In recent years thinner and shorter needles have been 
developed, making the injection less painful.  
• Dosage: Wash your hands before measuring and injecting insulin. 
Insulin is measured in units marked on the side of the syringe. 
This lets you measure the exact number of units that your doctor 
has ordered for you. Before injecting each dose, clean the 
injection site with rubbing alcohol.  
• Time of dosing:  The rapid-acting insulin should be given within 5 to 15 minutes before or after a meal. Premeal 
hypoglycemia may occur if the time between injection and eating is much greater than 15 minutes.  
• Storage: Insulin vials do not require refrigeration while in use but should be kept at room temperature [below    
       86°F (30°C)] away from direct heat and light. Insulin vials not in use should be   
       stored in a refrigerator, but not in the freezer.  
• Side effects/Safety: The most common side effects of insulin therapies are low 
blood sugar (hypoglycemia) and weight gain. Other possible side effects include 
reactions at the injection site (like redness, swelling and itching). 
• This type of insulin has been available for years and has been shown to be safe 
in controlling or managing blood glucose levels. 
• Costs: The average patient out of pocket monthly cost of taking insulin via vial 
and syringe is approximately $15-$30 per month. 
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INSULIN THERAPY USING INSULIN PENS - easy to carry, dose and use 
Insulin pens are similar to a syringe in that they have a needle at the tip of the pen and the insulin is pre-loaded in the 
pen. Therefore, it does not require the patient to draw the insulin when taking a shot.  It also eliminates the need to 
carry a vial. 
• There are two basic types: disposable and reusable. Disposable pens 
come already filled with insulin, whereas re-usable pens have a 
replaceable cartridge of insulin. 
• The pens make it easier for patients to measure correct insulin dose 
which can be conveniently dialed up and often afford the elderly and 
visually impaired a greater degree of independence   
• Pen offers less injection pain than a syringe  
• Dosage: no need to draw an insulin dose since the pen has the vial of 
insulin built in. You simply turn a dial to the desired dose, insert the needle and press a plunger to inject the 
insulin. You replace the needle before each injection.  
• Time of dosing:  The rapid-acting insulin should be given within 5 to   
     15 minute before or after a meal. Premeal hypoglycemia may occur  
       if the time between injection and eating is much greater than 15      
       minutes. 
• Storage: They do not require refrigeration while in use but should be 
kept at room temperature [below 86°F (30°C)] away from direct heat 
and light. Pens not in use should be stored in a refrigerator, but not in 
the freezer. 
• Side effects/Safety: The most common side effects of insulin therapy 
are low blood sugar (hypoglycemia) and weight gain. Other possible 
side effects include reactions at the injection site (like redness, 
swelling and itching).  
• This type of insulin has been available for years and has been showed to be safe in controlling or managing 
blood glucose levels. 
• Costs: The average patient out of pocket cost of taking insulin via pen is approximately $15-$30 per month. 
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INSULIN THERAPY USING INHALED INSULIN – designed to allow a more flexible lifestyle 
• The insulin is taken using a palm sized device. 
• This device allows rapid acting mealtime insulin to be 
inhaled, which dissolves in the lung and then travels into 
the bloodstream.  
• The device is light in weight, discreet and easy to use and 
carry. 
• Dosage: Patients put insulin doses pre-packaged in 
cartridges into the inhaler and turn the mouthpiece to 
release the insulin. 
• Time of dosing: It should be given within 5 to 15 minutes 
before or after a meal. 
• Storage: Should be kept at room temperature [below 
86°F (30°C)]. Do not refrigerate or freeze. 
• Side effects/Safety: Compared to insulin taken as a shot via syringe or pen, inhaled insulin has a lower risk of 
low blood sugar (hypoglycemia) and weight gain.  When taken by the inhaled route, this insulin acts like the 
insulin produced by the body and therefore the high and lows in sugar levels are less, even when individuals 
inhale it and don’t eat. May need to be avoided in smokers and patients with unstable or poorly controlled lung 
disease. 
• Costs: The average patient out of pocket cost of taking insulin via inhaled insulin is approximately $25-$45 per 
month. 
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